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ARTICLE
PRISONERS AS HUMAN SUBJECTS: A
CLOSER LOOK AT THE INSTITUTE OF
MEDICINE’S RECOMMENDATIONS TO
LOOSEN CURRENT RESTRICTIONS ON
USING PRISONERS IN SCIENTIFIC
RESEARCH
Osagie K. Obasogie†
There have been notable discussions within scientific literature, bioethics
scholarship, and the popular press regarding the Institute of Medicine’s (IOM)
2006 recommendations to the Department of Health and Human Services to
loosen federal restrictions on using prisoners in biomedical and behavioral
research. Yet there has been little dialogue among legal scholars about the
recommendations’ potential impact on administrative policy. Supporters point to
the growing need for clinical trial participants, ethicists’ changing perspectives,
and greater institutional protections, while opponents point to past abuses and
their likelihood to reoccur. Although certainly at odds, a common underlying
theme in this debate is a focus on the possible outcomes produced by these
recommendations rather than examining the argument made by the IOM
Committee in proposing changes to 45 C.F.R. § 46, Subpart C. While valuable,
this focus on possible outcomes might obscure a critical question that has thus far
remained relatively unexamined: did the IOM come to this recommendation for a
substantial shift in regulatory policy in a rigorous manner? As part of a broader
effort to think about ethics’ evolving relationship with administrative policy, this
Article takes a closer look at the ethical framework used to justify these
recommendations. Central to this inquiry is whether a proposed ethical
framework that (a) is based upon a literature review of scholarship rather than
an empirical examination of prison conditions, (b) treats prisoners’ vulnerability
to abuse as solely a product of prison conditions without broader consideration
of how profit motives within the research industry might exacerbate these
concerns and (c) is isolated from other relevant normative commitments (such as
human rights) can appropriately inform regulatory policy. This Article argues

41

41_82_OBASOGIE-PRINTER PROOF.DOC

42

11/9/10 4:30 PM

STANFORD JOURNAL OF CIVIL RIGHTS & CIVIL LIBERTIES

[VI:1

that it cannot. Before considering any changes to Subpart C, the Article argues
that greater attention must be paid to how empirical methods can inform
research ethics in prison, the different contexts that heighten prisoners’
vulnerability as human subjects, and the relevance of human rights to research
ethics.
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II. THE INSTITUTE OF MEDICINE AND ITS RECOMMENDATION TO
LOOSEN CURRENT RESTRICTIONS ON PRISON RESEARCH ...............48
A. Background to the Current Regulatory Restrictions: Past
Abuses wth Using Prisoners as Human Subjects ......................49
B. Mounting Concerns and Current Regulatory Framework............53
C. The 2006 IOM Report and Its “Evolved” Ethical Framework
for Evaluating Prison Research .................................................57
III. BEYOND CONSEQUENCES: A CRITIQUE OF THE INSTITUTE OF
MEDICINE’S RECOMMENDATIONS ....................................................60
A. Existing Commentaries on the IOM Report ................................60
B. Three Critiques of the IOM’s Updated Ethical Framework.........62
1. Methodological Critique........................................................62
2. Contextual Critique ...............................................................71
3. Substantive Critique ..............................................................77
CONCLUSION ................................................................................................81

INTRODUCTION
Rapid advances in biomedical research and changing perspectives in
bioethics are leading to increased calls to reform many administrative policies
related to health care, drug development, and clinical trials. One critical yet
underexamined1 example of how evolving perspectives in research ethics are
† Associate Professor of Law, University of California, Hastings; Associate Adjunct
Professor, Department of Social and Behavioral Sciences, University of California, San
Francisco; Senior Fellow, Center for Genetics and Society. B.A. Yale University, J.D.
Columbia Law School, Ph.D. University of California, Berkeley. The author is grateful for
comments on early drafts from Ashutosh Bhagwhat, Marcy Darnovsky, Lisa Ikemoto, Karen
Maschke, Dorit Reiss, Keramet Reiter, Reuel Schiller, and David Winickoff.
1. While the IOM’s recommendations have received notable discussion in medical and
bioethics circles, a LexisNexis search shows that only a handful of law review articles
reference or discuss the report. See, e.g., Andrea Lynn Osganian, Limitations on Biomedical
and Behavioral Research Involving Prisoners: An Argument Supporting the Institute of
Medicine’s Recommendations to Revise Regulations, 34 NEW ENG. J. ON CRIM. & CIV.
CONFINEMENT 429 (2008); Gerald R. Prettyman, Jr., Ethical Reforms in Biotechnology
Research Regulations, 15 VA. J. SOC. POL’Y & L. 51 (2007); Seema Shah, How Legal
Injection Reform Constitutes Impermissible Research on Prisoners, 45 AM. CRIM. L. REV.
1101 (2008); Keramet Reiter, Comment, Experimentation on Prisoners: Persistent
Dilemmas in Rights and Regulations, 97 CAL. L. REV. 501 (2009); Rachel Wener, Comment,
Not Situated to Exercise Free Power of Choice: Human Subject Research in Prison Settings,
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calling for change in regulatory policy is the Institute of Medicine’s (IOM)
recommendations to the Department of Health and Human Services to loosen
federal restrictions (45 C.F.R. §§ 46.300 et seq.2) regarding the use of prisoners
as human subjects in biomedical, epidemiological, and behavioral research.3
Supporters point to the growing need for more clinical trial participants,4
improved institutional oversight and greater penetration of ethical values into
research norms and protocols since the current restrictions were implemented in
the 1970s,5 and prisoners’ ostensible right to be included in biomedical and
26 TEMP. J. SCI. TECH. & ENVTL. L. 365 (2007). In general, the non-legal scholarly
conversation on the ethics of prison research has not been particularly robust in recent years.
See, e.g., Kathleen Brewer-Smyth, Ethical, Regulatory, and Investigator Considerations in
Prison Research, 31 ADVANCES IN NURSING SCI. 119 (2008); K.C. Kalmbach and Phillip M.
Lyons Jr., Ethical and Legal Standards for Research in Prisons, 21 BEH. SCI. & L. 671
(2003); Amy B. Smoyer et al., Compensation for Incarcerated Research Participants:
Diverse State Policies Suggest A New Research Agenda, 99 AM. J. PUB. HEALTH 1746
(2009); Sara Wakai et. al., Conducting Research in Corrections: Challenges and Solutions,
27 BEH. SCI. & L. 743 (2009).
2. Research Involving Prisoners, 45 C.F.R. §§ 46.301-.306 (2009). For a list of
relevant Federal Regulations, see National Institutes of Health, Regulations and Ethical
Guidelines, http://ohsr.od.nih.gov/guidelines/45cfr46.html (last visited Nov. 11, 2009).
3. See generally COMM. ON ETHICAL CONSIDERATIONS FOR REVISIONS TO DHHS
REGULATIONS FOR PROTECTION OF PRISONERS INVOLVED IN RESEARCH, INST. OF MED.,
ETHICAL CONSIDERATIONS FOR RESEARCH INVOLVING PRISONERS (Lawrence O. Gostin et al.
eds., 2006) [hereinafter 2006 IOM REPORT]. While the IOM Committee’s intent is for its
recommendations to apply to all types of research with human subjects (biomedical,
social/behavioral, and epidemiological), this Article largely discusses the recommendations
in the context of biomedical research since (1) this type of research has the most significant
risks and, as result, is most fraught with ethical challenges and (2) most of the discussion
concerning the IOM Committee’s recommendations has referenced this context.
4. The FDA “is requiring more tests and longer tests of new drug candidates” and
“[b]iotechnology companies, thanks in part to the decoding of the human genome and other
advancements in drug-development technology, are generating a swelling pool of new drug
candidates that need to be tested.” John George, Drug Trials Cause Tribulations: Finding
Volunteers is Becoming Tougher Task, PHILA. BUS. J., Dec. 5, 2008, available at
http://philadelphia.bizjournals.com/philadelphia/stories/2008/12/08/story1.html.
Yet,
finding people . . . to test new drug products or medical devices is becoming more
challenging than ever before” because “adverse events — ranging from a teenager dying in a
University of Pennsylvania gene therapy study to Merck pulling its FDA-approved arthritis
pain medicine Vioxx off the market because of safety concerns — have tempered people’s
willingness to participate in clinical trials. Id.
5. According to Barron Lerner,
It is often said that those who ignore history are condemned to repeat it. But a decision to
retain current restrictions because of past abuses would ignore several important
developments. Since 1978, a network of institutional review boards has been established at
the National Institutes of Health, other governmental agencies, and research universities
throughout the country. With “informed consent” now common parlance, study subjects are
more aware of their rights. And, largely owing to the work of AIDS activists and breast
cancer activists, sick and at-risk persons, even those from potentially vulnerable populations,
now actively pursue participation in research protocols. Even though not all of these are
unambiguously positive, to ignore them and the opportunities they may afford prisoners
would be to regress. As the IOM report said, “Respect for prisoners also requires recognition
of their autonomy.”
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behavioral research.6 Critics tend to highlight past abuses and their likelihood
to repeat themselves.7
While at odds, this conversation’s high stakes have led both sides to largely
focus on the possible outcomes of this proposed shift rather than to look more
carefully at how normative claims emanating from ethics discourses are being
leveraged to recommend substantial changes to regulatory policy. While it
would be an overstatement to say that the prison research debate has been
wholly consequentialist in nature, the current framing nonetheless takes the
recommendations largely at face value without examining how the Institute of
Medicine reasoned to its recommendations after 265 pages of ethical
deliberation. This raises a central question: What methods, approaches, and
assumptions did the IOM rely upon in recommending that current restrictions
should be loosened?8 Was the IOM’s approach to research ethics—in terms of
the methods used, the social contexts it identified as relevant to the issue, and
the normative paradigms chosen to inform its decision-making—robust enough
to justify overturning thirty years of regulatory precedent?
This Article argues that it was not. Biomedical and research ethics offer
many contributions for thinking through the proper relationship between
doctors and patients as well as governments’ role in protecting human subjects
in scientific research.9 While ethics certainly has a place in policy discussions,
Barron H. Lerner, Subjects or Objects? Prisoners and Human Experimentation, 356 NEW
ENG. J. MED. 1806, 1807 (2007).
6. The exclusion of seriously ill prisoners from clinical trials through which they may
receive potentially life-saving treatment is constitutionally dubious and morally troubling. It
is arguable that prisoners have a right to participation under the Eighth Amendment, the Due
Process Clause, and the promise of Equal Protection. In addition, moral considerations impel
the allowance of prisoner enrollment in therapeutic biomedical research.

Sharona Hoffman, Beneficial and Unusual Punishment: An Argument in Support of Prisoner
Participation in Clinical Trials, 33 IND. L. REV. 475, 515 (2000). See generally David L.
Thomas, Prisoner Research: Looking Back or Looking Forward?, 24 BIOETHICS 23 (2010).
7. The United States has a lengthy history of abusing prisoners in the name of medical
research. It was this well-documented history that led to the near prohibition of federally
funded prisoner medical experimentation by the 1970s. The Institute of Medicine’s proposal
to loosen these recommendations is ill-advised and shows a poor understanding of the
modern American prison system.

Paul Wright, Op-Ed., Look Elsewhere For Subjects, USA TODAY, Aug. 22, 2006, at 10A.
8. While the IOM characterizes its recommendation as strengthening oversight
mechanisms for research with prisoners, I use the term “loosen” to specifically describe the
IOM’s proposed shift from prisoners’ categorical restriction to a risk/benefit approach.
Compared to current regulations, this shift would likely lead to a substantial increase in the
number of prisoners participating in scientific research. See infra Part II.C.
9. For example, Kuhse and Singer note that bioethics “is a more overtly critical and
reflective enterprise” that is distinguished in three different ways:
First, its goal is not the development of, or adherence to, a code or set of precepts, but a better
understanding of the issues. Second, it is prepared to ask deep philosophical questions about the
nature of ethics, the value of life, what it is to be a person, the significance of being human. Third,
it embraces issues of public policy and the direction and control of science.

Helga Kuhse & Peter Singer, What is Bioethics? A Historical Introduction, in A COMPANION
TO BIOETHICS 4 (Helga Kuhse & Peter Singer eds., Blackwell 2001) (1998).
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this Article argues that it is not in and of itself a sufficient basis from which to
develop public policy. This is where the IOM Committee’s report misses the
mark. The IOM Committee largely treats its report as a scholarly exercise in
ethics that should be adopted as regulatory policy rather than embracing its role
as an independent government advisor that can provide the necessary
bridgework to bring ethical inquiries into public policymaking in a robust and
credible manner. This shortcoming is evident in at least three ways. First, from
a methodological standpoint, the IOM Committee forgoes taking a serious
empirical assessment (i.e. collecting primary data) of modern prison conditions
and instead bases its updated ethical framework on a literature review of
scholarly papers. Second, in terms of having an appropriate context from which
to understand the ethics of prison research, the IOM Committee only situates its
ethical inquiries into prisoners’ vulnerability by looking at prisons’ shifting
demographics (racial disparities, health inequalities, etc.) without examining
how shifting market conditions may lead researchers to treat vulnerable human
subjects in a less than virtuous manner. Lastly, the IOM Committee does not
meaningfully acknowledge other substantive sources that inform normative
commitments to human subject protection outside of research ethics or
biomedical ethics—namely human rights. Taken together, these
methodological, contextual, and substantive critiques suggest that the IOM’s
recommendations leave too much to be desired before they can meaningfully
inform regulatory policy.
This Article’s critique is broken into three parts. Part I briefly describes the
Institute of Medicine in terms of its history, organization, and modern influence
on health policy. After outlining the history of prisoners’ participation in
scientific research in the twentieth century and the regulations implemented in
the 1970s to oversee this practice, Part II describes the recommendations put
forth by the Institute of Medicine as well as the updated ethical framework used
to reach this conclusion. Part III then provides an extended discussion of the
methodological, contextual, and substantive shortcomings of the Institute of
Medicine’s ethical framework and recommendations. While these three
critiques overlap at points, they nonetheless provide a useful analytic
mechanism to think through the report’s limitations. This Article concludes by
discussing how ethical inquiries can best serve future public policymaking
endeavors.
I. THE INSTITUTE OF MEDICINE: ORGANIZATION, STRUCTURE, AND INFLUENCE
Positions taken by the Institute of Medicine carry significant weight as
recommended public policy due to the IOM’s unique history and organizational
structure. The IOM is one of four organizations that constitute the National
Academies.10 The first of these organizations—the National Academy of
10. The other organizations are the National Academy of Sciences, the National
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Sciences (NAS)—was established after the Civil War for the specific purpose
of advising the nation on matters of science. President Lincoln signed the Act
of Incorporation on March 3, 1863. Section 3 of the Act lays out the basic
parameters of the NAS:
The Academy shall, whenever called upon by any department of the
Government, investigate, examine, experiment, and report upon any subject of
science or art, the actual expense of such investigations, examinations,
experiments, and reports to be paid from appropriations which may be made
for the purpose, but the Academy shall receive no compensation whatever for
any services to the Government of the United States.11

The National Academy of Sciences broadened its scope throughout the
twentieth century at the request of several presidents to provide additional
scientific advice to government. Under the original charter, the National
Research Council was created in 1916 to “improve government decision
making and public policy, increase public education and understanding, and
promote the acquisition and dissemination of knowledge in matters involving
science, engineering, technology, and health.”12 Also under the same charter
signed by Lincoln, the National Academy of Engineering was founded in 1964
to “provide[] engineering leadership in service to the nation.”13 It is comprised
of over 2000 peer-elected members who provide expert research and analysis to
many levels of government.
Membership in the Institute of Medicine, which was founded in 1970, is
highly selective and quite prestigious. As both an honorific society and a nonprofit organization charged with providing guidance to government on
biomedical science, health, and medicine, the IOM has a strong reputation as an
independent consultant to government. Indeed, the Institute of Medicine’s
stated mission is to “serve[] as adviser to the nation to improve health,” which
it does by providing “unbiased and authoritative advice to decision makers and
the public.”14
The Institute of Medicine is organized in a manner that emphasizes
impartiality and objectivity in its recommendations. It is a private, nongovernmental organization that does not receive any direct federal money for
its services. The majority of its studies are conducted at the request of
government agencies who then fund the work out of the federal appropriations
Academy of Engineering, and the National Research Council. See The National Academies,
http://www.nationalacademies.org/about/ (last visited Jan. 25, 2010).
11. See National Academies of Science, About the NAS: Incorporation,
http://www.nasonline.org/site/PageServer?pagename=ABOUT_incorporation (last visited
Jan. 25, 2010).
12. National Research Council, http://sites.nationalacademies.org/NRC/ (last visited
Nov. 20, 2009).
13. National Academy of Engineering, About the NAE, http://www.nae.edu/About.
aspx (last visited Jan. 23, 2010).
14. Institute of Medicine, About the IOM, http://www.iom.edu/About-IOM.aspx (last
visited Jan. 24, 2010).
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made available to them.15 State and local governments, foundations, and other
independent organizations also suggest and provide support for studies.16 IOM
members are elected by their peers based upon their scientific accomplishments
and serve without compensation.17
Much of the IOM’s influence and credibility comes from the rigorous
study process behind each of its reports.18 This careful scholarly approach to its
research along with its organizational structure allows the IOM’s reports and
recommendations to have widespread influence among policymakers. Indeed,
this influence is precisely why the federal government established the IOM and
why their opinion is so highly sought: to affect policymaking.19
Examples of this policy influence abound. The IOM’s Dietary Reference
Intake20 provided “the scientific basis for the 2005 Dietary Guidelines for
Americans—the government’s primary nutrition policy document . . . [and is]
also credited with contributing to the removal of trans fats from foods.”21
Saving Lives Buying Time,22 an IOM study on malaria drugs and their
economics, is largely credited with “convinc[ing] a coalition of organizations,
including the World Health Organization and the World Bank, to develop a
worldwide subsidy program to make antimalarial drugs more affordable and
available.”23 The Institute of Medicine engaged in a study on the quality of
health care with its 2001 report entitled Crossing the Quality Chasm.24 Part of
this series entailed a report on medical errors, which “inspired the creation of
patient safety centers in several states to track and analyze data on hospital
errors.”25 And an IOM Study entitled Injury in America26 “was a major
15. See generally THE NATIONAL ACADEMIES, OUR STUDY PROCESS, available at
http://www.nationalacademies.org/studycommitteprocess.pdf.
16. See id.
17. INST. OF MED., INFORMING THE FUTURE: CRITICAL ISSUES IN HEALTH 2 (5th Ed.
2009), available at http://www.iom.edu/~/media/Files/Informing%20the%20Future%202009
.ashx.
18. See generally THE NATIONAL ACADEMIES, OUR STUDY PROCESS, supra note 15.
19. The IOM’s work is organized into seventeen topic areas, including mental health,
child health, public policy, public health and prevention, and minority health. See, e.g.,
National Information Center on Health Services and Health Care Technology, Introduction
to Health Services Research: A Self-Study Course, available at http://www.nlm.nih.gov
/nichsr/ihcm/03players/players16.html (last visited Jan. 25, 2010).
20. PANEL ON DIETARY REFERENCE INTAKES FOR ELECTROLYTES AND WATER,
INSTITUTE OF MEDICINE, DIETARY REFERENCE INTAKES FOR WATER, POTASSIUM, SODIUM,
CHLORIDE, AND SULFATE (2004).
21. INST. OF MED., ABOUT THE INSTITUTE OF MEDICINE: ADVISING THE NATION.
IMPROVING HEALTH (on file with author) [hereinafter ADVISING THE NATION].
22. COMM. ON THE ECONOMICS OF ANTIMALARIAL DRUGS, INST. OF MED., SAVING
LIVES, BUYING TIME: ECONOMICS OF MALARIA DRUGS IN AN AGE OF RESISTANCE (Kenneth J.
Arrow, et al. eds., 2004).
23. ADVISING THE NATION, supra note 21.
24. COMM. ON QUALITY OF HEALTH CARE IN AM., INST. OF MED., CROSSING THE
QUALITY CHASM: A NEW HEALTH SYSTEM FOR THE 21ST CENTURY (6th prtg. 2005).
25. ADVISING THE NATION, supra note 21.
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contributor to the development of the injury control and prevention field.”27 To
be sure,
soon after Injury in America was released, Congress appropriated funds for a
pilot program for injury control at CDC, and two years later, a new IOM-NRC
[National Research Council] committee reviewed its progress. In Injury
Control (NRC, 1988), the committee concluded that the program had been
sufficiently successful to warrant permanent support. It commended the CDC
program for establishing five interdisciplinary research centers; sponsoring a
new program of extramural research; and building staff expertise for
intramural research, database development, coordination, and technical
assistance.28

While the Institute of Medicine’s effect on policymaking is not easily
quantifiable, this anecdotal evidence along with its organizational mandate and
structure suggests that it continues to have a significant influence on
government decision-making. This also suggests that the Institute of
Medicine’s recommendations concerning the loosening of restrictions on using
prisoners in scientific research should be taken seriously; a long line of
evidence implies that there is a strong likelihood that the federal government
will give these recommendations careful consideration.29
II. THE INSTITUTE OF MEDICINE AND ITS RECOMMENDATION TO LOOSEN
CURRENT RESTRICTIONS ON PRISON RESEARCH
In 2004, the Department of Health and Human Services’ (DHHS) Office
for Human Research Protections commissioned the Institute of Medicine to
“review the ethics regarding research involving prisoners.”30 In particular, the
Institute of Medicine was charged with “examin[ing] whether the conclusions
reached in 1976 by the National Commission for the Protection of Human
Subjects of Biomedical and Behavioral Research [1976 Commission] remain
appropriate today.”31 The 1976 Commission was convened following the
revelation of significant abuses in scientific research as a way to improve
government oversight and human subject protection. To the extent that it is
widely acknowledged that the 1976 Commission’s report “was the basis for 45
26. COMM. ON TRAUMA RESEARCH, INST. OF MED., INJURY IN AMERICA: A CONTINUING
PUBLIC HEALTH PROBLEM (1985).
27. ADVISING THE NATION, supra note 21.
28. COMM. ON INJURY PREVENTION AND CONTROL, INST. OF MED., REDUCING THE
BURDEN OF INJURY: ADVANCING PREVENTION AND TREATMENT 20 (Richard J. Bonnie et al.
eds., 1999).
29. In a personal communication with Julia Gorey, Subpart C coordinator at the Office
for Human Research Protections, she noted that no changes have been made to federal
regulations based upon the IOM report but that changes to Subpart C are still under
consideration. Communication with Julia Gorey, Office of Human Research Protections
(Oct. 15, 2010) (on file with author).
30. 2006 IOM REPORT, supra note 3, at ix.
31. Id. at 22.
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C.F.R. § 46”32—which provides federal regulations for human subjects
research—and that the agency commissioning the report (DHHS) is the
regulatory body that oversees and enforces these regulations,33 the IOM report
has been largely seen as a serious attempt to rethink current restrictions on
using prisoners in human subjects research.34
The IOM report is the most recent chapter in a much longer conversation
on using prisoners as human subjects. Before engaging in a detailed critique of
the report, it is first necessary to (1) have a brief yet careful understanding of
the history of conducting scientific research in American prisons and (2)
engage in a close reading of the 1976 Commission’s report to appreciate the
sensibilities leading to the current regulatory framework found at 45 C.F.R. §
46, Subpart C.
A. Background to the Current Regulatory Restrictions: Past Abuses wth Using
Prisoners as Human Subjects
Prisoners’ participation in biomedical and behavioral research was
common in the United States throughout most of the twentieth century. Today,
we largely associate unethical practices such as not obtaining subjects’ consent
and coercion with Nazi medicine’s ghastly horrors.35 But these practices were
32. Id. at 22-23.
33. The Office for Human Research Protections (OHRP) provides leadership in the protection of
the rights, welfare, and wellbeing of subjects involved in research conducted or supported by the
U.S. Department of Health and Human Services (HHS). OHRP helps ensure this by providing
clarification and guidance, developing educational programs and materials, maintaining regulatory
oversight, and providing advice on ethical and regulatory issues in biomedical and behavioral
research.

U.S. DEP’T OF HEALTH AND HUMAN SERVICES, OFFICE FOR HUMAN RESEARCH
PROTECTIONS FACT SHEET, available at http://www.hhs.gov/ohrp/about/ohrpfactsheet.htm
(last visited May 2, 2010).
34. The Institute of Medicine provides the following background to the commissioning
of this report:
The OHRP’s responsibilities include implementation of the DHHS Regulations for the
Protection of Human Subjects . . . and the provision of guidance on ethical issues in
biomedical and behavioral research. OHRP has oversight and educational responsibilities
wherever DHHS funds are used to conduct research involving human participants. The
Secretary’s Advisory Committee for Human Research Protections (SACHRP), the advisory
committee to OHRP, has asked OHRP to rewrite Subpart C, taking into consideration the
current prison environment.
OHRP recommended that, before such an effort is undertaken, there should be a thorough
review of the ethical considerations in research involving prisoners, which could serve as the
basis for developing new regulations. Beyond its importance regarding revisions to Subpart
C, such a review would be instructive for developing ethical bases for making future changes
to the DHHS Regulations for the Protection of Human Subjects and the Common Rule.

2006 IOM REPORT, supra note 3, at 24.
35. See generally THE NAZI DOCTORS AND THE NUREMBERG CODE: HUMAN RIGHTS IN
HUMAN EXPERIMENTATION (George J. Annas & Michael A. Grodin eds., 1992) (discussing
the implications of the Nuremberg trial and the subsequent impact of the Nuremberg Code
on research ethics and international human rights). Annas and Grodin write,
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far from unique to the Holocaust;36 ethical lapses led popular drugs such as
Retin-A to be developed literally on prisoners’ backs before being
mainstreamed into many Americans’ drug cabinets.37 To be sure, the
questionable practices giving rise to the dramatic postwar increase in American
prisoners’ human subject participation predated the Nuremberg trials by nearly
half a century.
As early as 1906, Dr. Richard P. Strong—director of the Biological
Laboratory of the Philippine Bureau of Science who later became a professor of
tropical medicine at Harvard—gave a cholera vaccine to twenty-four Filipino
inmates without their consent in order to learn about the disease; thirteen died.38
Though this provides an early modern example of using prisoners as human
subjects, it certainly was not the last. Twelve inmates from Mississippi’s
Rankin Farm prison became test subjects in 1915 to study pellagra—a
disfiguring and deadly disease characterized by skin rashes and diarrhea.
Though common wisdom at the time suggested that pellagra was a disease
caused by germs, Dr. Joseph Goldberger—a physician in the federal
government’s Hygienic Laboratory, predecessor to the National Institutes of
Health—thought it was linked to malnutrition characteristic of Southern rural
poverty. After Mississippi Governor Earl Brewer promised pardons to all
participants—an inducement to participate in research that would be intolerable
today—Goldberger tried to prove his theory that poor diet caused pellagra by
subjecting inmates to what many called a “hellish experiment”: eating
exclusively high-starch foods such as “corn bread, mush, collards, sweet
[t]he most important historical forum for questioning the permissible limits of human
experimentation was the trial of Nazi physicians in post-World War II Nuremberg, Germany.
The trial provided the occasion for a substantive analysis of ethical standards. The physicians
and professors prosecuted at Nuremberg represent a frightening example of medicine gone
wrong. The extent of human experimentation, atrocities, and murders that were recorded
during the trials is inescapable.

Id. at 3.
36. [T]he Nazis were not the only ones to involve doctors in evil. One need only look at the role
of Soviet psychiatrists in diagnosing dissenters as mentally ill and incarcerating them in mental
hospitals; of doctors in Chile (as documented by Amnesty International) serving as torturers; of
Japanese doctors performing medical experiments and vivisection on prisoners during the Second
World War; of white South African doctors falsifying medical reports of blacks tortured or killed
in prison; of American physicians and psychologists employed by the Central Intelligence Agency
in the recent past for unethical medical and psychological experiments involving drugs and mind
manipulation; and of the “idealistic” young physician-member of the People’s Temple cult in
Guyana preparing the poison (a mixture of cyanide and Kool–Aid) for the combined murdersuicide in 1978 of almost a thousand people. Doctors in general, it would seem, can all too readily
take part in the efforts of fanatical, demagogic, or surreptitious groups to control matters of thought
and feeling, and of living and dying.

ROBERT JAY LIFTON, THE NAZI DOCTORS: MEDICAL KILLING AND THE PSYCHOLOGY OF
GENOCIDE xii (1986).
37. See generally ALLEN M. HORNBLUM, ACRES OF SKIN: HUMAN EXPERIMENTS AT
HOLMESBURG PRISON 211-31 (1998).
38. See generally Eli Chernin, Richard Pearson Strong and the Iatrogenic Plague
Disaster in Bilibid Prison, Manila, 1906, 11 REV. INFECTIOUS DISEASES 996, 996 (1989).
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potatoes, grits and rice” that caused considerable pain, lethargy, and dizziness.39
Despite their pleadings to end the study, prisoners were not allowed to
withdraw.40 And, in an early 1920s experiment that was as bizarre as it was
gratuitous, 500 inmates at California’s San Quentin prison had testicular glands
from rams, boars, and goats implanted into their scrotums to see if their lost
sexual potency could be rejuvenated.41
Though rare in the early twentieth century, these experiments highlight
basic breaches in human subject protections that would be unconscionable
under modern rules: the cholera test subjects had no idea what they were being
infected with, the prisoners in the pellagra study were not allowed to stop their
participation despite enduring substantial pain, and the San Quentin study’s
purpose and mechanism were questionable. In all, prisoners were used during
the early 1900s as convenience populations that had little control over their
own health and welfare.
World War II turned these small-scale endeavors into “considerably
larger[,] broad-scale investigations that were adequately funded and wellstaffed.”42 The war played a central role in giving legitimacy to unbridled
human experimentation in prisons.43 One infamous study was the Stateville
Prison Experiments, where researchers deliberately infected over 400 state
inmates with malaria in order to test treatments that were considered urgent for
39. HORNBLUM, supra note 37, at 78.
40. HORNBLUM, supra note 37, at 78-79. Hornblum writes,
Goldberger would not allow [the prisoners to be returned to the general prison population].
They had volunteered; they would have to stay the course regardless of the physical
consequences. [Soon] the first skin lesions began to appear and by the end of the month all of
the men showed signs of a rash on their hands, faces, and scrotums, the typical markings of
pellagra.

Id., at 78.
41. In 1918,
Leo Stanley, resident physician of San Quentin prison in California . . . began transplanting
testes removed from recently executed prisoners into older inmates, who in most cases
testified to the recovery of sexual potency and the alleviation of many other illnesses. In 1920
the “scarcity of human material” prompted him to substitute goat, deer and boar testes, which
appeared to work equally well.

E.J. Barten & D.W.W. Newling, Transplantation of the Testis; From the Past to the Present,
19 INT’L J. OF ANDROLOGY 205, 206 (1996).
42. HORNBLUM, supra note 37, at 80.
43. Hornblum writes,
The war years had become the transforming moment for human experimentation in America
and particularly for penal institutions as a site of such scientific endeavors. What had once
been a small, underfunded, unsophisticated cottage industry had blossomed into a well
financed, broad clinical research programme investigating avant garde procedures, cures, and
treatments. Human experimentation had been legitimised and prisoners had become the
guinea pigs of choice for scores of inspired researchers. Public opposition to such medical
initiatives was scant. The overriding goal was to win the war in Europe and Asia; everything
else was secondary, including research ethics and the issue of consent. Millions of American
fighters were risking life and limb daily; at the very least, lawbreakers could contribute to the
war effort with similar commitment. And they did.

Allen M. Hornblum, They Were Cheap and Available: Prisoners as Research Subjects in
Twentieth Century America, 315 BRIT. MED. J. 1437, 1440 (1997).
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aiding the war effort. The Stateville Experiments were troubling for many
reasons. For example, investigators—led by the University of Chicago’s Dr.
Alf S. Alving—used confusing consent forms to coax inmates into being
injected with a life-threatening disease. Participation was also rewarded; 317 of
the 432 inmates, including twenty-four murderers and one rapist, had their
sentences commutated after participating.44
Other wartime human subject research involving prisoners included efforts
to find treatments for gonorrhea, gangrene, and influenza in addition to testing
ultraviolet radiation’s effectiveness in killing airborne germs. The apparent
patriotism and selflessness surrounding prisoners’ wartime volunteering not
only led human experimentation to go unquestioned, but also led it to be seen
as an affirmative good.45
Prisoner experiments skyrocketed in the post-war era. Despite the horrific
stories that came out of the Nuremberg trials and other narratives detailing Nazi
research practices, medical researchers in the United States continued to go
about their business without giving much thought to the Nuremberg Code or
other emerging ethical principles.46 American exceptionalism and the
increasing profit motive stemming from rapidly expanding research industries
clouded opportunities for self-reflection, leading to inmates’ continued
exposure to dangerous research.47 This included radioactive blood tests, live
44. HORNBLUM, supra note 37, at 83.
45. For example,
[t]he U.S. Penitentiary at Atlanta, Georgia, played a critical role in the fight to conquer
malaria and approached the challenge as if it were ‘a major military engagement.’ . . .
.[Inmates were informed by government authorities] that malaria infection was taking a toll
on American soldiers far in excess of Japanese soldiers.
Approximately 600 of Atlanta’s 2,000 inmates volunteered to become ‘human guinea
pigs and undergo malarial infection and treatment with new drugs that were untried on the
human system.’
...
. . . Nearing the end of the experiment a reporter trumpeted the prison’s malaria project as
‘another shining light in the galaxy of wartime achievements at Atlanta.’

Id. at 83-84.
46. “The Nuremberg Code was widely regarded as ‘a good code for barbarians but an
unnecessary code for ordinary physicians.’ . . . In general, there appeared to be a broad
refusal among American medical scientists to draw lessons regarding their own actions from
the Nuremberg medical trial.” Bruce Gordon & Ernest Prentice, Protection of Human
Subjects in the United States, 6 J. PUB. HEALTH MGMT. 1, 3 (2000).
47. Hornblum writes,
[O]nce the war was over, there was no decline of medical experimentation in prisons.
Battlefield victories were replaced by medical triumphs as the focus of governmental
concern, and prisoners were once again the subjects of choice for research. The eradication of
disease had become the enemy, and postwar budgetary priorities supported this societal
mission. For example, in the last year of the war, the National Institute of Health received
about $700,000, which had climbed to $36 million by 1955, and over 10 times that just 10
years later. In 1970, $1.5 billion was awarded to some 11,000 grant applicants, nearly a third
of them performing experimentation. Called “the gilded age of research” by Professor David
Rothman, this new era of laissez-faire attitudes in the laboratory ushered in a frenzy for
research on prisoners that lasted for over a quarter century. Rothman argues that a “utilitarian
ethic” was able to dominate the field of human experimentation because “the benefits seemed
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cancer cell injections, and even behavioral and mind control experiments. It
was not uncommon for inmates to be either purposely given a disease or kept
from safer alternatives in order to test experimental drugs or procedures. This
quickly became standard fare: according to some reports, ninety percent of all
new pharmaceuticals were tested on prisoners until the 1970s.48
B. Mounting Concerns and Current Regulatory Framework
Sensibilities began to shift in the 1970s with a number of revelations
regarding the unethical treatment of vulnerable communities—both prisoners
and non-prisoners. The growing criticism of human subjects research among
the general population was ushered in by a number of events,49 but none so
striking as the Tuskegee experiment where rural Black men with syphilis were
deliberately left untreated so that researchers could study the course of the
disease.50 However, public exposure of what was happening within prisons also
played a key role. For example, it was during this period that the Holmesburg
Prison experiments became public—where an array of human subjects studies
coordinated in large part by the University of Pennsylvania used prisoners to
explore everything from shampoo and deodorants to dioxin and chemical
warfare materials. Major pharmaceutical companies were involved, such as
Dow Chemical and RJ Reynolds, not to mention the United States Army.51
With these revelations came the National Commission for the Protection of
Human Subjects of Biomedical and Behavioral Research. This commission was
created by the National Research Act, Pub. L. No. 93-348, 88 Stat. 342 (1974),

so much greater than the costs” and because “there were no groups or individuals
prominently opposing such an ethic.

Hornblum, supra note 43, at 1439.
48. Ian Urbina, Panel Suggests Using Inmates in Drug Trials, N.Y TIMES, Aug. 13,
2006, § 1, at 1.
49. By the early 1970s, social and political indifference to human experimentation had
begun to shift. Events as disparate as drug scares (thalidomide), hospital embarrassments (the
use of 22 senile patients for live cancer cell studies at the Jewish Chronic Disease Hospital in
New York City), alarming articles in professional journals (Dr Henry Beecher’s analysis of
unethical medical studies), and popular books (Jessica Mitford’s Kind and Usual
Punishment) contributed to a growing repugnance towards scientific experiments on
unwitting and institutionalized populations.

Hornblum, supra note 43, 1440.
50. Susan M. Reverby writes,
In the counties surrounding [Tuskegee, Alabama], the U.S. Public Health Service ran a
forty-year study, from 1932 to 1972, of “untreated syphilis in the male Negro,” while telling
the men in the study that they were being “treated” for their “bad blood.” The outcry over the
study, which affected approximately 399 African-American men with the disease and 201
controls, led to a lawsuit, Senate hearings, a federal investigation, and new rules about
informed consent. It provided a powerful metaphor for racism, ethical mistakes, and the
danger of state-run medical research.

Susan M. Reverby, More Than Fact and Fiction: Cultural Memory and the Tuskegee
Syphilis Study, 31 THE HASTINGS CTR. REP. 22 (2001).
51. See generally HORNBLUM, supra note 37.
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to “develop ethical guidelines for the conduct of research involving human
subjects and to make recommendations for the application of such guidelines to
research conducted or supported by [what is now called the Department of
Health and Human Services.]”52 The Commission based its recommendations,
published in 1976, on an examination of “the conditions under which such
research is conducted, and the possible grounds for continuation, restriction or
termination of such research.”53 To do this, “members and staff made site visits
to four prisons and two research facilities outside prisons that use prisoners, in
order to obtain first-hand information on the conduct of biomedical research
and the operation of behavioral programs in these settings.”54 These visits
included interviews with prisoners who had participated in research while
incarcerated as well as with non-participants.55
For the Commission, the task of developing ethical practices was as much
of an empirical investigation56 as a principled one.57 These site visits provided a
grounded assessment58 for what the Commission considered to be the key
ethical consideration regarding prisoners’ human subject participation: “(1)
whether prisoners bear a fair share of the burdens and receive a fair share of the
benefits of research; and (2) whether prisoners are, in the words of the
Nuremberg Code, ‘so situated as to be able to exercise free power of choice’—
that is, whether prisoners can give truly voluntary consent to participate in
52. NAT’L COMM’N FOR THE PROTECTION OF HUMAN SUBJECTS OF BIOMEDICAL AND
BEHAVIORAL RESEARCH, REP. AND RECOMMENDATIONS: RESEARCH INVOLVING PRISONERS vii
(1976) [hereinafter 1976 COMMISSION REPORT].
53. Id. at viii.
54. Id.
55. Id.
56. The Commission took pains to visit and survey different types of prisons across the
country so that its recommendations would be informed by prisoners’ diverse experiences
and institutional situations. They visited the State Prison of Southern Michigan at Jackson,
which at the time was the largest prison in the United States with over 5000 inmates. To
have a sense of behavioral programs operating in a prison setting, the Commission visited a
unit of the Washington State Penitentiary at Walla Walla and the Michigan Intensive
Program Center at Marquette. They also visited the California Medical Facility at Vacaville,
which mostly held prisoners referred there for medical or psychiatric reasons. Id., at 33, 39.
57. In their influential text on biomedical ethics, Tom Beauchamp and James Childress
identify respect for autonomy, non-maleficence, beneficence, and justice as the four
principles approach to biomedical ethics, which has become known as ‘principlism.’ They
note that “the four principles derive from considered judgments in the common morality and
medical traditions.” TOM L. BEAUCHAMP & JAMES F. CHILDRESS, PRINCIPLES OF BIOMEDICAL
ETHICS 23 (5th ed. 2001).
58. In the 1976 Commission report,
[T]he Commission has noted and cannot ignore serious deficiencies in living conditions
and health care that generally prevail in prisons. Nor can the Commission ignore the potential
for arbitrary exercise of authority by prison officials and for unreasonable restriction of
communication to and from prisoners. The Commission, although acknowledging that it has
neither the expertise nor the mandate for prison reform, nevertheless urges that unjust and
inhumane conditions be eliminated from all prisons, whether or not research activities are
conducted or contemplated.

1976 COMMISSION REPORT, supra note 52, at 5.
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research.”59 By explicitly referencing the Nuremburg Code, the Commission
implied that the abuses conducted by American physicians and researchers
raised concerns similar to those raised by scientists put on trial after World War
II. To the extent that the American research industry did not see itself in this
manner, drawing upon the Nuremburg Code to ground recommendations for
American physicians’ behavior was a profound paradigm shift. To be sure, the
Commission notes, “it is within the context of a concern to implement these
principles that the Commission has deliberated the question of use of prisoners
as research subjects.”60
This sensibility led the Commission to take a protectionist approach in
providing recommendations regarding prisoners’ participation in biomedical
and behavioral research.61 In applying the basic ethical principles of justice
(“that persons and groups be treated fairly”)62 and respect for persons (“that the
autonomy of persons be promoted and protected”)63 the Commission forwent
other interpretations and favored the protection of prisoners from abuse and
exploitation:
When persons seem regularly to engage in activities which, were they stronger
or in better circumstances, they would avoid, respect dictates that they be
protected against those forces that appear to compel their choices. It has
become evident to the Commission that, although prisoners who participate in
research affirm that they do so freely, the conditions of social and economic
deprivation in which they live compromise their freedom. The Commission
believes, therefore, that the appropriate expression of respect consists in
protection from exploitation. Hence it calls for certain safeguards intended to
reduce the elements of constraint under which prisoners give consent and
suggests that certain kinds of research would not be permitted where such
safeguards cannot be assured.
Further, a concern for justice raises the question whether social institutions
are so arranged that particular persons or groups are burdened with marked
disadvantages or deprived of certain benefits for reasons unrelated to their
merit, contribution, deserts or need. . . . To the extent that participation in
research may be a burden, the Commission is concerned to ensure that this
burden not be unduly visited upon prisoners simply because of their captive
status and administrative availability.64
59. Id.
60. Id. at 6.
61. The Commission notes,
[r]eflection upon [the principles of justice and respect for persons] and upon the actual
conditions of imprisonment in our society has led the Commission to believe that prisoners
are, as a consequence of being prisoners, more subject to coerced choice and more readily
available for the imposition of burdens which others will not willingly bear. Thus, it has
inclined toward protection as the most appropriate expression of respect for prisoners as
persons and toward redistribution of those burdens of risk and inconvenience which are
presently concentrated upon prisoners.

Id. at 8.
62. Id. at 5.
63. Id. at 5-6.
64. Id. at 6-7 (emphasis added).
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While the Commission’s definitions of “justice” and “respect for persons” as
motivating ethical principles may seem vague, they nonetheless gave substance
to its protectionist approach that, in turn, led to five key recommendations.65
The Belmont Report66 informed new rules in the Code of Federal
Regulations that strengthened all human subject protections.67 Additional
subparts were added to provide specific protections for research involving
vulnerable subjects—pregnant women, human fetuses, and neonates (Subpart
B); prisoners (Subpart C); and children (Subpart D). Established in 1978,
Subpart C reflects many of the recommendations put forth by the 1976
Commission. It permits research with prisoners only when it falls within one of

65. See generally id., ch. 2. The commission’s recommendations can be summarized as
follows: (1) Studies of the possible causes, effects, and processes of incarceration and
prisons as institutions may be conducted if they only present minimal risk or inconvenience
to subjects. (2) Research on practices that are intended to improve prisoners’ health or wellbeing are permitted. (3) Other studies that fall outside of the aforementioned parameters
should not be permitted unless (a) they fulfill an important need and there are compelling
reasons to use prisoners; (b) conditions of equity support the use of prisoners; and (c) there is
a high degree of voluntariness among participants and openness by the institution. (4) The
head of the responsible federal department should determine the investigators’ competency
and the adequacy of the research facilities. Moreover, all research proposals involving
prisoners should be approved by an Institutional Review Board (IRB). (5) Ongoing research
projects that fall underneath the third recommendation shall continue until one year from the
recommendations’ publication or their completion, whichever comes first.
66. On July 12, 1974, the National Research Act (Pub. L. 93-348) was signed into law,
there-by [sic] creating the National Commission for the Protection of Human Subjects of
Biomedical and Behavioral Research. One of the charges to the Commission was to identify
the basic ethical principles that should underlie the conduct of biomedical and behavioral
research involving human subjects and to develop guidelines which should be followed to
assure that such research is conducted in accordance with those principles. In carrying out the
above, the Commission was directed to consider: (i) the boundaries between biomedical and
behavioral research and the accepted and routine practice of medicine, (ii) the role of
assessment of risk-benefit criteria in the determination of the appropriateness of research
involving human subjects, (iii) appropriate guidelines for the selection of human subjects for
participation in such research and (iv) the nature and definition of informed consent in
various research settings.
The Belmont Report attempts to summarize the basic ethical principles identified by the
Commission in the course of its deliberations. It is the outgrowth of an intensive four-day
period of discussions that were held in February 1976 at the Smithsonian Institution’s
Belmont Conference Center supplemented by the monthly deliberations of the Commission
that were held over a period of nearly four years. It is a statement of basic ethical principles
and guidelines that should assist in resolving the ethical problems that surround the conduct
of research with human subjects. By publishing the Report in the Federal Register, and
providing reprints upon request, the Secretary intends that it may be made readily available
to scientists, members of Institutional Review Boards, and Federal employees. . . .
Unlike most other reports of the Commission, the Belmont Report does not make
specific recommendations for administrative action by the Secretary of Health, Education,
and Welfare. Rather, the Commission recommended that the Belmont Report be adopted in
its entirety, as a statement of the Department’s policy.

NAT’L COMM’N FOR THE PROTECTION OF HUMAN SUBJECTS OF BIOMEDICAL AND BEHAVIORAL
RESEARCH, THE BELMONT REPORT: ETHICAL PRINCIPLES AND GUIDELINES FOR THE
PROTECTION OF HUMAN SUBJECTS (1979), available at http://ohsr.od.nih.gov/guidelines
/belmont.html [hereinafter BELMONT REPORT].
67. 45 C.F.R § 46 (2009).
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four categories:
1. Studying the possible causes, effects, and processes of incarceration
and/or criminal behavior,
2. Studying prisons as institutional structures or prisoners as incarcerated
persons
3. Research on conditions that particularly affect prisoners as a class, and
4. Research developed to improve subjects’ health and well-being.
Minimal risk, or that the potential harm does not exceed what one might
encounter in daily life or routine medical examination, is this subpart’s general
standard. Under this framework (which only applies to research funded or
conducted by the Department of Health and Human Services, Social Security
Administration, CIA, or voluntarily compliant institutions68), “the default
position is that no such research should occur, and the four or five categories of
research allowed under the regulations are essentially exceptions to that general
rule.”69
C. The 2006 IOM Report and Its “Evolved” Ethical Framework for Evaluating
Prison Research
The Institute of Medicine’s 2006 report, Ethical Considerations for
Research Involving Prisoners, was commissioned by the Department of Health
and Human Services, whereby the charge of the Committee “was to explore
whether the conclusions reached in 1976 . . . remain appropriate today.”70
Weighing in at 265 pages, the report takes what appears to be an exhaustive
look at all of the issues involved. Concluding that current restrictions should be
loosened while boosting overall oversight, the IOM makes five major
recommendations:
1. Expand the definition of prisoner
2. Ensure universal, consistent ethical protection
3. Shift from a category-based to a risk benefit approach to research
review
4. Update the framework to include collaborative responsibility (e.g.
developing research in collaboration with prisoners and prison staff)
5. Enhancing oversight of research involving prisoners
The first and last two recommendations are largely uncontroversial if not
unequivocally beneficial in and of themselves. The first two, expanding
oversight by including persons under any aspect of criminal justice supervision
and ensuring universal ethical guidelines are surely an improvement over
today’s patchwork of federal, state, and local rules. The last two, bringing
68. Lawrence O. Gostin, Biomedical Research Involving Prisoners: Ethical Values and
Legal Regulation, 297 JAMA 737 (2007).
69. 2006 IOM REPORT, supra note 3, at 73.
70. Id. at ix.
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prisoners into the research process as collaborators and strengthening IRB
oversight, will similarly find few opponents. The third recommendation—
shifting from prisoners’ almost categorical exclusion from research to a more
permissive risk/benefit analysis—is where the ethical road meets the legal
rubber. As such, this recommendation will be the focus of this Section.
In describing how the 1976 Commission developed the current restrictions,
the IOM report acknowledges the “commission’s emphasis on limiting research
involving prisoners was guided by its choice of ethical framework.”71 Although
the 2006 IOM Committee uses the term “ethical framework” throughout the
report to both define core aspects of the 1976 Commission’s work and
recommend substantial changes through an alternative approach, the IOM
Committee does not define this concept precisely. A fair and plain reading of
the IOM Committee’s usage of the term suggests that “ethical framework” is
used to denote the ethical principles that guide each panels’ decision making
with regards to the normative claims made about prisoner participation in
scientific research.
As discussed earlier, current regulations (informed by the 1976
Commission’s ethical framework and findings) prioritize justice—defined here
as whether prisoners are treated fairly and whether they bear a fair share of the
research benefits and burdens—and respect for persons, which questions
whether prisoners have enough personal autonomy to give voluntary consent.
In short, the 1976 Commission felt that prison was no place to conduct
widespread scientific research. The 2006 IOM Committee starts by creating “an
updated ethical framework” based upon its conclusion that “ideas about justice
and respect for persons have evolved over the past three decades.”72 Put
differently, the 2006 Committee sidesteps the threshold issue concerning prison
conditions presented by the 1976 Commission and instead asks whether ideas
about ethical principles have changed. Its first evolutionary update is to
“question[] the myopia caused by . . . a narrow focus”73 on informed consent.
After reviewing a handful of articles, the Committee notes, “[m]ore attention
needs to be paid to risks and risk-benefit analysis rather than the formalities of
an informed consent document.”74 This shapes the major recommendation to
stop thinking of prisoners as a category of individuals who, by default, should
not be human subjects. Instead, the Committee recommends looking at each
research proposal on a case-by-case basis to assess its potential risks and
benefits.75 The Committee’s second evolutionary update is to expand justice
71.
72.
73.
74.

Id. at 115.
2006 IOM REPORT, supra note 3, at 113, 116.
Id. at 117.
Id. at 118. While a risk/benefit approach is a new proposal in the context of prison
research, such analyses are not uncommon in other aspects of human subjects research. See
CARL H. COLEMAN ET AL., THE ETHICS OF REGULATION OF RESEARCH WITH HUMAN SUBJECTS
ch. 6 (2005).
75. The IOM Committee argues, “The risks and benefits of human subjects research
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from its original meaning in 1976 to now include collaborative responsibility,
or that prisoners be able to give input on research design.
This shift from a substantive approach to justice and respect for persons
(emphasizing protection, fairness, and burden-sharing) to a more procedural
mechanism (emphasizing representation, along with the noncategorical
risk/benefit analysis) constitutes the IOM Committee’s “evolved” or “updated”
ethical framework. These changes represent the revised first principles from
which the Committee recommends loosening current human subject restrictions
for prisoners. The Committee believes that prisoners’ participation should no
longer be highly restricted simply because they are prisoners, which runs
directly against the 1976 Commission’s concern with prisoners as a category of
human subjects to the extent “that the status of being a prisoner makes possible
the perpetration of certain systemic injustices.”76 The 2006 IOM Committee
suggests changing regulatory policies to cut in a different, more permissive
direction: the benefits and risks of research should be weighed independently
before a decision is made.
Before moving on to a critique of this shift away from prisoners’
categorical restrictions to a risk/benefit approach, it is important to note that the
IOM Committee recognizes the concerns that may stem from its
recommendations. Not only does it dedicate an entire chapter of the report to
discussing oversight mechanisms and safeguards to accompany the
recommendations, but it also provides specific guidance for conducting
biomedical research with prisoners, which potentially carries the most risks.77
Here, the IOM Committee recommends that in applying the risk/benefit
framework in prison contexts, there should already be evidence of safety and
efficacy (e.g., Phase III testing) and the ratio of prisoners to non-prisoners used
in the study should not exceed fifty percent.78 (The Committee notes that these
rules can be disregarded “in exceptional circumstances” and with additional
safeguards.79) The IOM Committee emphasizes that biomedical research in
prisons should only be done to benefit individual prisoners; inmates should not
be used as a convenience population. While these additional protections are
notable, this Article’s focus is on how the IOM Committee reasoned to the
ethical propriety of its proposed risk/benefit approach to displace longstanding
categorical restrictions, not the procedural mechanisms and limitations
developed afterwards.

are the ethically relevant issues, not the category of the research.” 2006 IOM REPORT, supra
note 3, at 123. The Committee acknowledges that “weighing risks against benefits is
inherently subjective,” but that such analysis should be based upon data to identify “the
types of potential harms and benefits, their probability of occurrence, and their long term
consequences.” Id. at 118.
76. 1976 COMMISSION REPORT, supra note 52, at 7.
77. See generally 2006 IOM REPORT, supra note 3, ch. 6.
78. Id. at 126.
79. Id.
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III. BEYOND CONSEQUENCES: A CRITIQUE OF THE INSTITUTE OF MEDICINE’S
RECOMMENDATIONS
In an effort to assess the prevailing level of discourse and criticism, this
Part begins by examining some of the commentaries published in scientific and
public outlets in reaction to the Institute of Medicine’s recommendations. After
highlighting the largely consequentialist nature of this commentary, this Part
offers a critical assessment that draws attention to significant shortcomings in
the IOM’s approach that have yet to be discussed.
A. Existing Commentaries on the IOM Report
The Institute of Medicine’s updated ethical framework and
recommendations have not been discussed widely in legal literature, and the
attention they have received in the scientific community,80 ethics scholarship,81
and the popular press82 has been limited. While perspectives have been mixed,
there has not been a robust scholarly critique of the reasoning and methodology
behind the IOM’s proposed ethical stance on prisoners’ participation as human
subjects. Georgetown Law Professor Lawrence Gostin, who chaired the 2006
IOM Committee, wrote in the Journal of the American Medical Association
(JAMA) that despite valid concerns, “[t]he opening of otherwise closed
institutions to outside health professionals . . . could increase transparency and
public accountability. Research can help society better understand how to
improve prisoners’ chances to succeed.”83 Since the current regulations only
apply to research supported or conducted by a handful or federal agencies and
voluntary compliant organizations, the vast majority of prison-related research
occurs with little oversight. Therefore, Gostin argues, the 2006 IOM
Committee’s recommendations actually expand regulation by bringing all
research involving incarcerated persons under the same framework. Barron H.
Lerner agreed with the IOM Committee’s assessment in the New England
Journal of Medicine, writing, “[t]he panel’s decision makes sense for several
reasons.”84 Lerner notes that “despite the findings at Nuremberg and occasional
other warnings, human experimentation was largely seen as a ‘good,’
80. See, e.g., Samuel Loewenberg, US Advisory Panel Revisits Prison Research Rules,
368 THE LANCET 1143 (2006); Emily Waltz, US Ponders Unlocking the Gates to Prisoner
Research, 12 NATURE MEDICINE 3 (2006).
81. See, e.g., Eric Chwang, Against Risk-Benefit Review of Prisoner Research, 24
BIOETHICS 14 (2010); Bernice S. Elger & Anne Spaulding, Research on Prisoners: A
Comparison Between the IOM Committee Recommendations (2006) and European
Regulations, 24 BIOETHICS 1 (2010); Thomas, supra note 6.
82. See, e.g., Jeffrey Brainard, Report Calls for Easing Rules on Research Involving
Prisoners, 52 CHRON. HIGHER EDUC., July 28, 2006, at A16; Urbina, supra note 48, at 1.
83. Gostin, supra note 68, at 739.
84. Barron H. Lerner, Subjects or Objects? Prisoners and Human Experimentation,
356 NEW ENG. J. MED. 1806, 1807 (2007).
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something that would advance science and benefit health.”85 To the extent that
abuses took place during previous periods, Lerner argues that the advent of
Institutional Review Boards in the late 1970s provides sufficient protection to
prevent their reoccurrence. Moreover, Lerner argues that the idea that prisons
are coercive environments that mitigate ideals such as informed consent “is a
theory that can and should be investigated empirically,” and coercive elements
are present in all research regardless of subjects’ imprisonment.86 Therefore, as
another commentator notes, it is not uncommon within the research literature
for people to conclude that the “type[s] of oversight described [by Lerner and
Gostin], as well as in the Institute of Medicine Report, are likely to yield the
benefits to incarcerated persons and minimize the risks of abuse.”87
At first blush, it is striking that two prominent medical journals published
articles strongly supporting a more permissive approach to using prisoners in
scientific research. This type of support can also be seen in the bioethics
literature. For example, David Thomas makes a familiar argument in the
journal Bioethics that access to clinical trials give prisoners access to cutting
edge therapies; denying this access simply because they are incarcerated may
itself be unethical.88 Other commentators, however, have taken a more sober
approach. Paul Wright, founder and editor of Prison Legal News, writes, “the
key element to any ethical system of human subject testing is informed,
voluntary consent. Prisons and jails fail on all counts. All 50 states and the
federal government have banned sex among prisoners and staff because
detention facilities are inherently coercive, and prisoners cannot give ‘consent’
in any meaningful sense of the word.”89 As the editor for a magazine that takes
a human rights approach to incarceration, Wright is noticeably concerned that
looser restrictions will result in abuses similar to those that occurred in the past.
Investigative journalist Sonia Shah, an expert on the outsourcing of clinical
trials to the developing world, argues that the Institute of Medicine’s
recommendations have less to do with improving prisoners’ health or giving
them access to cutting edge research and more to do with giving
pharmaceutical companies access to human subjects when other volunteers are
scarce. Moreover, Shah is not convinced that the IOM’s proposal for increased
oversight for biomedical research in prison settings—such as limiting prisoner
participation to Phase III trials and requiring that prisoners make up no more
than half of all trial participants—are meaningful in light of broader

85. Id.
86. Id.
87. Josiah D. Rich, Health Issues in Prisons and Jails, 84 J. URB. HEALTH 740, 741

(2007).
88. “[I]t is the feeling of many practitioners that the only way cutting edge therapy can
be given to the incarcerated is through offering clinical trials in the prison setting. Likewise,
denying them the advantages of cutting-edge treatments would be tantamount to abridging
their rights only because of their incarcerated situation.” Thomas, supra note 6, at 25.
89. Wright, supra note 7, at 10A.
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dynamics.90
B. Three Critiques of the IOM’s Updated Ethical Framework
While the possible outcomes of the Institute of Medicine’s
recommendations have received considerable attention, there has been little, if
any, critique of the evolved or updated ethical framework developed by the
Institute of Medicine to justify its more permissive approach. Put differently,
how did the Committee come to its decision? What were the Committee’s
reasons for supplanting the 1976 Commission’s ethical framework? How do
they justify recommending a substantial departure from thirty years of
regulatory policies regarding prisoners’ participation as human subjects? Are
the reasons and ethical principles behind these justifications persuasive? Are
there any limitations with the logic behind the IOM Committee’s new ethical
framework? The Institute of Medicine report is certainly laudable in attempting
to provide better oversight for prisoners’ participation as human subjects and
reviewing whether the ethical commitments made three decades ago still serve
prisoners’ best interest. Yet, there are at least three key critiques of the
committee’s approach—spanning its methods, context, and substance—that
raise serious questions about the Institute of Medicine’s more permissive
ethical framework.
1. Methodological Critique
How we come to a particular decision is often as important as the decision
itself. Thus, what is meant by critiquing the methods behind the Institute of
Medicine’s report is to investigate the data, assumptions, conclusions, and
arguments that inform the ethical choices that are made. What process did the

90. For example, Shah discusses the difficulty of recruitment:
The bottleneck for drugmakers is in recruiting warm bodies for late-phase trials that
establish a new product’s effectiveness with statistical certainty. These “Phase 3” trials can
require tens of thousands of patients to complete, and most drug-saturated Americans are
reluctant to take part. Eighty percent of trials fail to meet recruitment deadlines, bleeding
drugmakers of $1 million a day while their blockbuster wannabes remain locked up in
development.
To solve the dilemma, many drugmakers have rushed overseas, to places like India and
Poland, where sick, desperate patients are abundant. Now, if the institute’s recommendations
hold sway, they’ll be able to access the 7 million souls captive to the US correctional system
as well. The institute’s proposed caveat that prisoner experiments include subjects from
outside prison walls as well will make little practical difference in such trials. Few, if any,
drugmakers would want to restrict these huge trials to prisoners anyway.

Sonia Shah, Op-Ed., Testing Drugs on Prisoners: The Easy Out, BOSTON GLOBE, Aug. 17,
2006, at A13. See also Leda M. Perez & Henrie M. Treadwell, Determining What We Stand
For Will Guide What We Do: Community Priorities, Ethical Research Paradigms, and
Research With Vulnerable Communities, 99 AM. J. PUB. HEALTH 201 (2009) (arguing that
“until the question of adequate health care for prisoners is resolved, human experimentation
should not be allowed.”).
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Institute of Medicine Committee engage in to identify, collect, and analyze the
data that informs its recommendations? And was this process robust enough to
form the basis for a new ethical framework that suggests significant policy
changes?
The first methodological issue concerning the Institute of Medicine’s
updated ethical framework stems from the fact that the Committee “visited one
prison and one prison medical facility to discuss experimentation with current
prisoners and peer educators.”91 This rather cursory first-hand look at the
modern conditions of prison life is a stark contrast to the more in-depth
examination made by the 1976 Commission, which based its recommendations
on conditions observed during four site visits made to different types of prisons
across the country. The 1976 Commission based its assessment on an empirical
investigation into prisoners’ lived conditions and developed an ethical
framework of protectionism that evolved out of its grounded assessment that
basic ethical norms of justice and respect for persons would be difficult to
achieve in a prison setting.92 Not only did the Institute of Medicine Committee
not replicate the methodological rigor behind this approach, they also did not
fully engage the conditional nature of the 1976 Commission’s sense of when
these restrictions should be lifted: “should coercions be lessened and more
equitable systems for the sharing of burdens and benefits be devised, respect
for persons and concern for justice would suggest that prisoners not be deprived
of the opportunity to participate in research.”93
The 2006 IOM Commission’s lack of engagement with this conditional
statement is notable. As a matter of precedent, that is where the 1976
Committee left the conversation. Ethic’s engagement with precedent—not
unlike precedent’s role in legal reasoning—can promote stability, consistency,
and predictability that ultimately protect the most vulnerable parties involved.
Many of the 2006 Committee’s recommendations can be read as providing a
more equitable system of burdens and benefits sharing. But the issue of
whether coercion has been lessened is an empirical question that is difficult to
answer with one site visit. Moreover, it is also difficult to come to any policy
recommendation—ethical in nature or otherwise—without committee members
taking a more serious first-hand look at the conditions shaping modern prison
life. This imperative is even more compelling if the committee’s leanings are to
contravene three decades of ethical and administrative precedent to loosen
restrictions initially developed to protect prisoners from exploitation. To the
IOM Committee’s credit, it did collect information from six state corrections
departments regarding their policies and practices pertaining to research with
prisoners.94 But, there is a strong argument—particularly when judged by the

91.
92.
93.
94.

2006 IOM REPORT, supra note 3, at 122.
See generally 1976 COMMISSION REPORT, supra note 52.
Id. at 8.
2006 IOM REPORT, supra note 3, at 59.
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standard set by the 1976 Commission—that this is insufficient for the
Committee to gain an adequate appreciation for the unique challenges posed by
conducting scientific research in a prison setting. This issue becomes even
more relevant once one takes into consideration that all available evidence
suggests that the conditions of prison life that might lead to coercion are
unlikely to have improved and are most likely to have worsened since 1976.95
This first critique concerning the Institute of Medicine’s cursory
assessment of modern prison life is inextricably intertwined with a second
methodological critique. Rather than engaging in an empirical understanding of
prison conditions and how this may affect prisoners’ participation in scientific
research, the Institute of Medicine relies heavily on shifting academic
perspectives to form its ethical framework. What is remarkable, however, is
that the Institute of Medicine Committee bases this new framework—which
drives its policy recommendation to loosen restrictions—not on a substantial
shift in the literature documenting prison experiences, but rather on what it
calls an evolution in the ethics literature:
Ideas about justice and respect for persons have evolved over the past three
decades. To construct a comprehensive ethical framework for thinking about
research in prisons, [we] explore[] recent research ethics scholarship. Changes
in the way these principles have been conceptualized have influenced the
shape of our recommendations.96

Put another way, the committee bases its recommendations largely on a
literature review. For example, the IOM Committee’s expanded view of respect
for persons was informed by “recent scholarship [that] has questioned the
myopia caused by such a narrow focus”97 on informed consent. They reference
Kahn, Mastroianni, and Sugarman’s edited volume Beyond Consent: Seeking
Justice in Research for the proposition that “[t]here seems to be agreement
from a variety of perspectives that informed consent forms have consumed too
much time and energy.”98 This leads the IOM Committee to question “whether
too much weight has been placed on informed consent in the framework of
research ethics and research regulation,”99 which ultimately leads them to state
that “questions about an undue focus on informed consent influence [its]
recommendations.”100 It is this literature review based critique of informed
consent that shapes the Committee’s most significant recommendation to
change current regulatory policy: the shift from treating prisoners as a
95. For discussions of prison ethnographies that provide a close analytical look at the
lived experiences of prisoners in today’s penal system, see, e.g., Jonathan Simon, The
‘Society of Captive’s in the Era of Hyper-Incarceration, 4 THEORETICAL CRIMINOLOGY 285
(2000); Loïc Wacquant, The Curious Eclipse of Prison Ethnography in the Age of Mass
Incarceration, 3 ETHNOGRAPHY 371 (2002).
96. 2006 IOM REPORT, supra note 3, at 116.
97. Id. at 117.
98. Id.
99. Id. at 118.
100. Id.
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categorically excluded group (with few exceptions) to a more permissive
risk/benefit assessment.101 Similarly, the IOM committee bases its
recommendation to shift from a strong protectionist model (which was highly
preferred by the 1976 Commission) to a moderate protectionist approach on the
notion that “[a]dvances in ethical thinking about protectionism suggest a new
regulatory model.”102 As a side note, it is interesting to point out that the IOM
Committee provides additional justification for its more moderate approach to
protectionism (and its ultimate recommendation to loosen restrictions) by
pointing to empirical data gathered by the 1976 Commission in which several
interviewed prisoners said that they appreciated the opportunity to participate in
research103—a sentiment corroborated by other prisoners during the IOM
Committee’s singular site visit. But what the IOM Committee fails to disclose
is the extent to which the 1976 Committee found prisoners’ apparent
willingness to participate irrelevant to the broader question of the ethics of
using prisoners in research given their particular circumstances. The 1976
Commission notes that it “did not find in prisons the conditions requisite for a
sufficiently high degree of voluntariness and openness, notwithstanding that
prisoners currently participating in research consider, in nearly all
circumstances, that they do so voluntarily and want the research to continue.”104
This methodological approach of using literature reviews as a basis for
developing regulatory policy also informs the IOM Committee’s approach to its
“evolved” understanding of justice. The first aspect of this evolution—
collaborative responsibility—stems from the Committee’s assessment that the
“conceptualization of justice has expanded since the original [1976]
commission’s work. They primarily thought of justice in terms of the
distribution of risks and benefits.”105 The IOM Committee shifts this take on
justice to include a concept of collaborative responsibility, which means that
multiple stakeholders such as prisoners and representatives from outside
community groups should participate in the conduct and design of research
101. “More attention needs to be paid to risks and risk-benefit analysis rather than the
formalities of an informed consent document.” Id.
102. Id. at 121.
103. The Institute of Medicine Committee notes that in 1975, commission members
spoke,
with a representative sample of research participants and nonparticipants selected by
commission staff from a master list of all prisoners [in Jackson State Prison] and found that,
overall, participants valued the opportunity to participate in research and felt they were
sufficiently informed and free to enroll or withdraw at will, and nonparticipants did not
object to this opportunity being available to others.

Id. at 121-122.
104. 1976 COMMISSION REPORT, supra note 52, at 12. With regards to the eagerness of
the Michigan inmates to participate, the 1976 Commission placed this enthusiasm in a
different context: “Participants gave many reasons for volunteering for research, including
better living conditions, need for good medical evaluation, and desire to perform a
worthwhile service to others, but it was clear that the overriding motivation was the money
they received for participating.” Id. at 35 (emphasis added).
105. 2006 IOM REPORT, supra note 3, at 127.
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proposals that include prisoners.106 Working from Lisa Eckenwiler’s 2001
article Moral Reasoning and the Review of Research Involving Human
Subjects, the committee embraces this perspective to counterbalance its
proposed risk/benefit shift away from prisoners’ categorical restrictions as
human subjects.107 The IOM Committee also references scholarly work by Alex
John London108 and Madison Powers109 to note that an evolved notion of justice
“requires that [research with prisoners] must be done in a setting in which there
is an adequate standard of health care in place.”110
Although the ethical evolution involved in the IOM Committee’s new
understanding of justice will find few objections, there are still significant
methodological problems with basing policy recommendations on literature
reviews, particularly with regards to the IOM Committee’s updated ethical
framework on respect for persons. While there is certainly a place for assessing
academic perspectives as part of the process of reviewing the adequacy of
current regulations, prisons are profoundly unique environments whose every
nuance and empirical reality must be brought into the policymaking process.
There is a strong argument that the focus of the Committee’s ethical
reasoning—that “[i]deas about justice and respect for persons have evolved
over the past three decades”111—misses the point. The question is not simply
whether academics, clinical practitioners, and other medical professionals have

106. The IOM Committee notes this
“involves acknowledging that groups are not monolithic and are themselves subject to a
range of problems that should be addressed in the consultation process. This recommendation
has two aspects: (1) including more lay people who match the local population and common
subject groups in key respects; and (2) shaping IRBs so they are hospitable places for lay
members.”

Id. at 128.
107. The IOM Committee writes,
[A] new risk-benefit approach needs to be accompanied by an emphasis on collaboration.
The ethical problems associated with research involving prisoners will manifest themselves
differently in each correctional setting. The one-size-fits-all approach characterized by a
focus on informed consent cannot adequately address the unique concerns presented by each
setting. Thus all relevant parties should be involved (prisoners, correctional officers, medical
staff, administrators) when creating and implementing a research protocol. This effort,
combined with a more specific focus on risks and benefits, can lead to research practices that
better incorporate justice and respect for persons.

Id. at 128-29.
108. Alex John London, Justice and the Human Development Approach to
International Research, 35 HASTINGS CTR. REP. 24 (2005).
109. Madison Powers, Theories of Justice in the Context of Research, in BEYOND
CONSENT: SEEKING JUSTICE IN RESEARCH 147-65 (Jeffrey P. Kahn et al. eds., 1998).
110. 2006 IOM REPORT, supra note 3, at 132. The committee notes,
that this expanded concept of justice is an important ethical development. Justice requires
more than the protection of prisoners from harm caused by the research itself. Ethical
research carries with it a responsibility to grapple with the fact that potential harm is
ubiquitous in everyday prison life, creating an environment for research in which the choice
to participate in a study can be inherently coercive and potentially dangerous.

Id.
111. Id. at 116.
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changed their minds, but more importantly whether the conditions giving rise to
the 1976 Commission’s ethical framework—such as coercion and lack of
privacy—have been substantively addressed. The IOM Committee does not
fully address this threshold question.
To be clear, the IOM certainly identifies the ways prisons have changed
since the 1976 Commission issued its report; an entire chapter in the IOM
report examines today’s prisons in terms of shifting demographics, health
issues, and the current environment.112 In addition to the prison and jail
population’s astronomical growth since restrictions in prisoners’ human subject
participation were implemented—from 454,444 inmates in 1978 to 2.1 million
in 2004—the committee dutifully notes a number of challenges to conducting
ethical human subjects research under these conditions. These include serious
overcrowding, racial and ethnic disparities, disproportionately high rates of
mental illness and chronic and infectious disease, poor health care, and high
rates of violence, rape, and suicide. Nearly twenty-five percent of all inmates
report being injured at least once since entering prison.113
What is concerning, however, is that the IOM isolates these conditions in
recommending greater oversight mechanisms—such as a public database for all
research with prisoners—without discussing how these conditions bear on its
chosen ethical framework, which drives its ultimate policy recommendation.
Put differently, the realities of prison life are separated from the Committee’s
investigations rather than integrated and grappled with as part of the
fundamental ethical inquiry. As an example, for a prisoner who is routinely
sexually assaulted by other prisoners—a situation not uncommon among
today’s inmates114—what does privacy and informed consent mean and how
would this shape said prisoner’s ability to freely participate in human subjects
research that might adversely affect his health? By limiting concerns over
prison conditions to questions of oversight rather than to the ethical propriety of
using prisoners as human subjects, the report gives little guidance as to how to
answer such questions.
But the issue with the literature-review-as-public-policymaking approach is
not simply that this method is problematic on its face, but also that the Institute
of Medicine Committee uses this problematic method in a particularly
problematic way. First and foremost, the literature review used to justify
recommendations for substantial regulatory policy changes was not as robust as
it could be. For example, to ground its claim that “[t]here seems to be
agreement from a variety of perspectives that informed consent forms have
consumed too much time and energy,”115 the IOM Committee points to one

112. See generally id.
113. See generally id. at 29-55.
114. See generally HUMAN RIGHTS WATCH, NO ESCAPE: MALE RAPE IN U.S. PRISONS

(2001).
115. 2006 IOM REPORT, supra note 3, at 117.
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edited volume.116 For such a broad statement about an entire scholarly field and
its wide reaching implications—beyond the question of using prisoners as
human subjects—it is reasonable to think that the IOM would engage in a more
nuanced discussion of this issue before concluding “[t]hese questions about an
undue focus on informed consent influence our recommendations.”117
But in addition to the less than comprehensive nature of the Institute of
Medicine’s literature review is the problem that very few of the key articles
relied upon to give legitimacy to its updated or evolved ethical framework
actually deal with the issue of conducting research in prisons.118 For example,
Ezekiel Emmanuel et al.’s JAMA article What Makes Clinical Research
Ethical? is heavily relied upon by the IOM Committee to justify its updated
ethical framework. It substantially redefines informed consent and displaces
categorical restrictions in favor of risk/benefit analyses. Yet, it does not discuss
the unique ethical challenges posed by using prisoners as human subjects.119
And, contrary to the Committee’s assertion that this article reflects the ethical
evolution it proposes, the author states in the opening paragraph that traditional
informed consent continues to “reflect[] the preponderance of existing guidance
on the ethical conduct of research,”120 which belies the Committee’s argument
that ethics as a field has evolved in a direction similar to its proposed
framework. Similarly, albeit less problematically, the IOM Committee
singularly cites Lisa Eckenwiler’s 2001 article as a basis for its evolved
perspective on justice including collaborative responsibility when Eckenwiler’s
discussion is not about the particular concerns raised by research in a prison
context.
These concerns point to substantial tensions within the IOM’s proposed
ethical framework. In its attempt to discuss the ethics of doing research in a
fraught and historically disfavored environment such as prisons, the IOM
Committee reviews literature written outside of the prison context that does not
address its particularities, abstracts the principles from this scholarship as
universally applicable, and then reincorporates them as morally and
116. See generally BEYOND CONSENT: SEEKING JUSTICE IN RESEARCH (Jeffrey P. Kahn
et al. eds., 1998). The IOM Committee cites to this one edited volume to ground its assertion
that there is a consensus perspective among ethicists regarding informed consent. They cite
to an article by Ezekiel Emanuel to discuss and ground an alternative risk/benefit approach,
which they ultimately embrace.
117. 2006 IOM REPORT, supra note 3, at 118.
118. One exception is Jonathan Moreno’s “Convenient and Captive Populations,”
which is part of the BEYOND CONSENT volume edited by Kahn et. al., which spends three and
a half pages on conducting research in prisons. Jonathan D. Moreno, Convenient and Captive
Populations, in BEYOND CONSENT: SEEKING JUSTICE IN RESEARCH 113-16 (Jeffrey P. Kahn et
al. eds., 1998). This article does not appear to have played a major role in the IOM’s
decision-making, unlike other articles that were written against a distinctly non-prison
backdrop.
119. Ezekiel J. Emanuel et al., What Makes Clinical Research Ethical? 283 JAMA
2701 (2000).
120. Id.
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situationally appropriate into an “updated” ethical framework that itself does
not meaningfully engage with modern prison conditions. This is a strained
methodology that privileges theory over lived conditions, which may very well
be disastrous given prisoners’ vulnerable position.
Nevertheless, the Institute of Medicine Committee may very well justify
this method of inquiry by highlighting that the task charged to it by the
Department of Health and Human Services was “to review the ethics regarding
research involving prisoners.”121 By emphasizing that ethics is a humanistic
field that has traditionally existed outside of empirical inquiries, the IOM might
defend its methods by arguing that ethical inquiries typically entail
philosophical investigation into the human condition that can be most clearly
ascertained through the relevant scholarly literature. Moreover, it may
reasonably defend its approach by saying that given the structure of its study
process as well as other institutional imperatives, the Committee is neither
equipped nor designed to engage the type of empirical scrutiny encouraged by
this Article.122
Yet, this explanation leaves much to be desired. While ethics is often
identified as a philosophical endeavor anterior to empirical social science, a
strong body of literature has developed over the past few decades that has led to
a growing movement of “empirical ethics” or “evidence-based ethics” that
entails “the application of research methods in the social sciences (such as
anthropology, epidemiology, psychology, and sociology) to the direct
examination of issues in bioethics.”123 Jacoby and Siminoff describe this shift
through discussing the work of Renee Fox:
[In 1989] Fox . . . produced an eloquent analysis of the relationship between
bioethics and the social sciences characterizing it as “ . . . tentative, distant and
susceptible to strain.” In her analysis, she described how each field contributed
to the tension—bioethics largely due to its focus on individualism and
equating the social sciences with a quantitative and non-humanistic
perspective, and the social sciences due to their limited interest in studying
values and beliefs and favoring structural and organizational variables which,
she contended, reduced their understanding of the importance of ethical and
moral values in society. Her conclusion was that the ethos of both fields, with
resultant “blind spots,” constituted barriers to collaboration and synergy.
Since this bleak picture was articulated two decades ago, the relationship
between the two fields has evolved to the point where bioethics is a
multidisciplinary field of study (as opposed to a singular discipline), where
moral philosophy, the medical sciences, the humanities, and the social
sciences intersect.124

121. 2006 IOM REPORT, supra note 3, at ix.
122. See generally THE NATIONAL ACADEMIES, OUR STUDY PROCESS, supra note 17.
123. Maya J. Goldenberg, Evidence Based Ethics? On Evidence-based Practice and

the ‘Empirical Turn’ From Normative Bioethics, 6:11 BMC MED. ETHICS 1, 2 (2005),
available at http://www.biomedcentral.com/1472-6939/6/11.
124. LIVA JACOBY & LAURA A. SMINOFF, EMPIRICAL METHODS FOR BIOETHICS: A
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Examples of the increasing incorporation of empirical methods into
bioethics abound.125 At bioethics’ inception as a modern field of study in the
mid 20th century, empirical methods were not widely used to explore issues
such as human subject protections due to social scientists’ initial detachment
from the field (which was then dominated by philosophers and theologians126),
communication disjunctions across disciplinary boundaries, and meta-ethical
distinctions between descriptive pursuits of “the is” and normative conclusions
over “the ought.”127 Indeed, it was believed that empiricists and bioethicists
operated in two distinct fields, where the former collected data and the latter
assessed them. But, the advantages of greater integration between the fields
quickly became apparent in its ability to supplement abstract theory with
practical accounts of reality. That is, it has become increasingly acknowledged
that credible accounts of what we ought to do should be grounded in an
accurate assessment of lived conditions. This is precisely the contribution
offered by empirical ethics.
Hence, while the IOM Committee may have identified certain evolutionary
trends in the field of ethics since the 1976 report, its failure to recognize this
major trend towards grounding ethics in empirical assessments and its
relevance to the Committee’s inquiry erects a substantial barrier to its
recommendations. To not pursue a serious empirical investigation of how
modern prison conditions shape the ethical question of research in this
environment—let alone recognize the importance of such an investigation in its
literature review—severely limits the report’s recommendations. Moreover,
even if one concedes that a literature review is an appropriate basis for
regulatory policymaking, then the review ought to be more substantive than
citing one or two articles as a basis for recommending changes to over three
decades of regulatory precedent. And if the study process for IOM Committees
PRIMER 2 (Liva Jacoby and Laura A. Siminoff eds., 2008).
125. For interesting overviews of the empirical turn in bioethics, see Richard E.
Ashcroft, Constructing Empirical Bioethics: Foucauldian Reflections on the Empirical Turn
in Bioethics Research, 11 HEALTH CARE ANALYSIS 3 (2003); Pacal Borry, Paul Schotsmans,
and Kris Dierickx, The Birth of the Empirical Turn in Bioethics, 19 BIOETHICS 49 (2005).
126. See generally ALBERT R. JONSEN, THE BIRTH OF BIOETHICS, chs. 2, 3 (1998).
127. Descriptive ethics is the field in which empirical data about moral issues are gathered.
It is the domain par excellence of sociology, anthropology, psychology, and epidemiology,
and it aims at describing peoples’ temporal values, rules, preferences, norms, and actions.
These disciplines describe how reality is constructed—they describe what ‘is.’ However,
they can never tell how people ought to behave, or what kinds of decisions are morally
acceptable. According to most authors, this fundamental distinction stems from a small
paragraph of David Hume’s Treatise of Human Nature (1740), and is traditionally called the
naturalistic fallacy. It is a logical mistake to infer a necessary conclusion from premises that
are contingent in their modality, or to assign contingency to a conclusion that is inferred from
premises that are necessary in their modality. The naturalistic fallacy consequently stresses
that it is false reasoning to draw an ought-conclusion from premises that entirely consist of
is-statements—one can never extrapolate an ‘ought’ from an ‘is.’ For this reason, ethicists
became convinced that the results of social science research could never be useful for ethical
reflection.

Borry, et al., supra note 125, at 60.
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cannot support empirical inquiries as basic as that which was pursued by the
1976 Commission (e.g. multiple site visits across diverse penal institutions),
then perhaps it is not the appropriate organization to weigh in on such issues.
2. Contextual Critique
The Institute of Medicine report uses past abuses with research in prisons
as the main basis from which to situate its recommendations. This means that
this history functions as the primary contextual backdrop informing how the
IOM understands the situation, the risks and dangers involved, and the sensitive
ethical terrain that needs to be navigated. This history provides a context that
informs every aspect of the report, perhaps as a way to demonstrate a
commitment to not allowing the past to become present. This is evident in
different ways. The most explicit example is the report’s second chapter, where
the Committee discusses current prison demographics, health issues, and
research environment in relation to the past.128 This chapter provides a veritable
laundry list of all the conditions that complicate the idea of conducting ethical
research in prison environments—and how these conditions have worsened in
just about every conceivable way. Health care is abysmal,129 the incarcerated
population has exploded and prisons are overcrowded,130 racial minorities are
disproportionately represented,131 the number of incarcerated women has

128. The second chapter’s opening sentence reads, “The conditions of confinement in
today’s prisons and jails have many of the same characteristics that were of concern to the
National Commission for the Protection of Human Subjects of Biomedical and Behavioral
Research . . . some 30 years ago.” 2006 IOM REPORT, supra note 3, at 29.
129. For example, the 2006 IOM report says,
Health care within some prison systems is less than satisfactory. . . . [A] federal district
court judge placed California’s entire prison medical health-care system into federal
receivership, taking it out of control of the state and placing it under the control of a trustee
appointed by the court. In addition, the entire state prison mental health system is being
monitored by another federal court after being found to be providing constitutionally
inadequate mental health services to inmates with serious mental illnesses. . . . And New
York regulators have faulted the private firm Prison Health Services in several deaths within
the state’s prison system.

Id. at 29-30.
130. The IOM Committee notes “the correctional population has expanded more than
4.5 fold between 1978 and 2004–from 1.5 million to almost 7 million. Prisons and jails
house 2.1 million prisoners; an additional 4.9 million are on probation and parole.” Id. at 58.
131. The report discusses racial disparities:
Blacks and Hispanics are disproportionately represented in prison and jail populations. At
midyear 2004, an estimated 12.6 percent of all black males in their late 20s were in prisons or
jails compared with 3.6 percent of Hispanic males and 1.7 percent of white males. Young
Black men are particularly hit hard. One in eight black men in their late 20s is incarcerated
on any given day. A report of the National Center on Institutions and Alternatives indicated
that in the District of Columbia, 50 percent of young black men ages 18 to 35 were under
criminal justice supervision (in prison, jail, probation, parole, out on bond, or being sought
on a warrant).

Id. at 38.
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increased significantly,132 and prisoners are routinely exposed to violence.133
But are changing prison demographics the only relevant context from
which to think through the ethical challenges presented by using incarcerated
people in scientific research? What is remarkable about how the IOM
conceptualizes prisoners’ vulnerability is that it frames it largely as a function
of “what happens in prisons” rather than the commercial forces that, in some
instances, can lead researchers to seek prisoners in the first place. Put
differently, the IOM Committee understands the potential for abuse stemming
only from prison conditions, not the market conditions that can make prisons
attractive places for research entities to find cheap and plentiful human subjects
and perhaps not uphold the highest ethical standards.
A bit of background may be helpful in understanding how the need for
more human subjects intersects with research interests that may exacerbate
prison research abuses. The same period that witnessed significant changes in
prison demographics and conditions overlaps with a period of substantial
changes in the pharmaceutical industry and clinical trial landscape. When Jonas
Salk developed a polio vaccine in 1954, over 1.8 million people became “Polio
Pioneers” by volunteering to test the experimental vaccination. People’s
goodwill and trust were key to finding an effective treatment. Yet, these
sentiments waned after the quickly approved vaccine was linked to accidentally
infecting 220 children with polio. This, along with other human subject
scandals such as Tuskegee, increased people’s skepticism and reluctance to
volunteer.
At the same time this human subject supply dwindled, genetic engineers
began developing biotech techniques that sparked innovation and drug
development. Sonia Shah notes, “[j]ust as the biotech revolution took off, the
pipeline turning those new compounds into sellable products had started to
clog.”134 There were “36,839 new clinical trials from 2001 to ‘04, six times
132. “Between 1980 and 1998, the number of female inmates under the jurisdiction of
federal and state correctional authorities increased more than 500 percent, from about 13,400
in 1980 to roughly 84,000 at year end 1998, according to the U.S. General Accounting
Office. In 2004, that number had risen to 104,848.” Id. at 35-36.
133. The report acknowledges that,
[p]risoners face violence and injury within correctional settings. More than one-quarter of
state and federal inmates reported being injured since admission to prison. The likelihood of
injury increases with time served in prison, as does the likelihood of a medical problem.
In 2000, there were 34,355 assaults by state and federal prisoners against other inmates,
and 51 prisoners died as a result of those violent actions. . . .
In 1999, nearly 22 percent of state inmates had a history of being injured while in
prison. Overall, 7 percent of state inmates were injured in a fight while in prison.
According to the 2003 Prison Rape Elimination Act, more than 1 million people have
been sexually assaulted in prisons over the past 20 years. The act also describes the
devastating effects of sexual assault in this context: an increase in other types of violence,
including murder, involving inmates and staff, and long-lasting trauma, which makes it even
more difficult for people to succeed in the community after release.

Id. at 47-48.
134. SONIA SHAH, THE BODY HUNTERS: TESTING NEW DRUGS

ON THE

WORLD’S

41_82_OBASOGIE-PRINTER PROOF.DOC

Apr. 2010]

11/9/10 4:30 PM

PRISONERS AS HUMAN SUBJECTS

73

more than in the period between 1981 to ‘85.”135 The rapid increase in drug
development diametrically opposed the diminishing number of human subjects,
creating considerable slowdowns in moving drugs from clinical trials to the
market.
This clog in the drug development pipeline has now turned into what many
consider to be a full-blown crisis. Hundreds of new drugs that might save or
improve lives are not reaching market as quickly as they might if human
subject supply met demand. Drug development has largely outpaced human
subject availability. But the crisis is not only humanitarian. It also affects the
pharmaceutical industry’s bottom line. Central to a conversation that is
ultimately about developing medicines to improve life is the reality that
pharmaceuticals are big business. According to the Fortune 500 annual ranking
of America’s largest corporations, pharmaceuticals had the third most
profitable return on revenues of any industry in 2007.136 Like any other forprofit endeavor, shareholders do not simply expect this performance to
continue. They expect it to improve.
Human subject shortages hamper drug companies’ humanitarian and
shareholder interests; as much as $5 million is lost each day a new medication’s
approval stalls, not to mention countless opportunities to improve patients’
lives.137 Eighty percent of all drugs tested on humans never receive FDA
approval, partly as a result of this shortage.138 While the pharmaceutical
industry did not play a formal role in the IOM’s recommendations, it would not
be implausible to think that the inadequate supply of human subjects, their high
demand, and the strong financial incentives to resolve this imbalance may have
influenced the sensibility to relax current restrictions:
Currently, there is a significant demand for pharmaceutical testing. From 1995
to 2005, the contract research industry, grown out of the increasing need for
subject recruitment for clinical trials, has grown from a 1 billion to a 7 billion
dollar per year industry. Along with increasing testing needs has come high
profile cases of drug toxicity, and these cases have created increased public
awareness about the need for study and surveillance of drug toxicity. For
example, it has been suggested that increased testing of Vioxx would have
prevented the delay in discovering its cardiovascular toxicity.139

Another financial pressure point exacerbating this human subject shortage
is lost revenues associated with expiring patent exclusivity. For example, when
POOREST PATIENTS 3 (2006).
135. David Evans et al., Big Pharma’s Shameful Secret, BLOOMBERG MARKETS, Dec.
2005, at 5.
136. Fortune 500 Most Profitable Industries 2008, FORTUNE, May 5, 2008, available at
http://money.cnn.com/magazines/fortune/fortune500/2008/performers/industries/profits/inde
x.html.
137. Evans et al., supra note 135, at 6.
138. Id.
139. Timothy J. Wiegand, Captive Subjects: Pharmaceutical Testing and Prisoners, 3
J. MED. TOXICOLOGY 37, 37 (2007).
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Schering-Plough lost U.S. exclusivity on Claritin in December 2002, sales fell
18% the following year; the company reported a net loss of $92 million
compared to a $1.97 billion profit the previous year when their Claritin patent
was secure.140 Market researchers estimate that drug companies making the 28
top selling drugs will lose upwards of $50 billion in revenue as their patents
expire between 2003-2008.141 The only way to stave off this tide is by
developing new drugs, performing clinical trials to obtain FDA approval, and
securing market exclusivity in new areas of pharmaceutical treatment. Human
subjects are not only essential to the continuing health of an aging population,
but also to these companies’ economic viability. Many pharmaceutical
companies are already trying to fulfill this need by outsourcing clinical trials to
developing countries.142 But more human subjects closer to home would surely
be beneficial.
It is surprising that the Institute of Medicine does not acknowledge how
profit motives and market dynamics can play as significant of a role as prison
conditions in giving rise to potentially abusive research environments. The
search for new blockbuster drugs is a powerful motivator for corporations
seeking to maintain their profitability. Sectors of the research industry
immediately recognized how loosened regulations concerning prisoners’
participation in scientific research can dramatically improve their bottom lines,
as noted in this pharmaceutical newsletter:
The pharmaceutical industry, who said it was not involved in the panel’s
decision, will be thrilled at the news, as it continues to struggle to recruit
enough suitable patients for clinical trials. Patient recruitment is now
consuming thirty per cent of clinical trial time—more time than any other
clinical trial activity—and almost half of all trial delays result from patient
recruitment problems. These delays are costing drug companies over half a
million dollars for specialty products and more than $8m (€6.7m) for
blockbuster brands in lost sales and are also causing the cost of running
clinical trials to skyrocket. Meanwhile, the 2.3m-strong US prison population
remains an untapped resource for patients who are perfect for clinical trials,
including racial minorities, women, as well as people with mental illness and
140. Evans et al., supra note 135, at 5.
141. Evans et al., supra note 135, at 5.
142. Shah writes,
Just as automakers and apparel manufacturers had fled the stringent labor and environmental
laws of the West to set up shop in the developing world, drug companies and [contract
research organizations] streamed across the border. Although companies aren’t required to
alert the FDA before testing their drugs on non-U.S. patients, nor does the FDA track
research by location after approving new drugs, it is clear that the tectonic plates have
shifted. Between 1990 and 1999 the number of foreign investigators seeking FDA approvals
increased sixteenfold, the Department of Health and Human Services’ Office of the Inspector
General found. By 2004, the FDA estimated, drug companies angling for FDA approval of
their new products were launching over sixteen hundred new trials overseas every year. The
most popular destinations are not Western Europe and Japan, but rather the broken,
impoverished countries of Eastern Europe and Latin America. Russia, India, South Africa,
and other Asian and African countries have proven equally fruitful.

SHAH, supra note 134, at 7.
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communicable diseases such as HIV/AIDS, hepatitis C, and tuberculosis.143

The crucial role that human subjects play in the profitability of research efforts
draws attention to the pressures that can lead to vulnerable populations’
questionable treatment by researchers.
The Institute of Medicine Committee may respond to the critique that
conditions beyond the immediate prison environment—such as the for profit
drug development industry—might complicate these ethical questions by
arguing that we should assume that researchers are virtuous in their endeavors.
Indeed, this presumption that researchers can be trusted to protect human
subjects drives the IOM Committee to move away from the strong protectionist
approach favored by the 1976 Commission and towards a moderate approach:
Advances in ethical thinking about protectionism suggest a new regulatory
model. In particular, the committee rejects strong protectionism because it
discounts the notion that researchers can be trusted to act virtuously in the
protection of subjects. Researchers have responsibility for protecting subjects
in their studies, especially those who are most vulnerable.144

While the IOM Committee acknowledges that “given the troubling history
of research abuse in prisons, weak protectionism is not an option,”145 the
Committee’s blind normative assertion of the research industry’s categorical
virtue may miss the point. Recommending that the protectionist sentiment
embedded in current regulations should be revoked in favor of an approach that
emphasizes placing the responsibility for human subject protection in the hands
of the very industry that stands to profit from loosened regulations raises
several questions concerning appropriate oversight.
Regardless, there have been and continue to be numerous examples of the
research industry’s failure to uphold basic research ethics regarding human
subject protection, which belie the IOM Committee’s categorical confidence in
preexisting institutional mechanisms. For example, an intriguing piece of
investigative journalism from a 2005 Bloomberg Markets special report details
how pharmaceutical companies engage private testing centers and private IRBs
to coordinate their research efforts, including the recruitment of test subjects.
The report notes:
The FDA’s own enforcement records portray a system of regulation so porous
that it has allowed rogue clinicians—some of whom have phony credentials—
to continue human drug tests for years, sometimes decades. The Fabre
Research Clinic in Houston, for example, conducted experimental drug tests
for two decades even as FDA inspectors documented the clinic had used
licensed employees and endangered people repeatedly since 1980. In 2002, the
FDA linked the clinic’s wrongdoing to the death of a test participant.

143. Kirsty Barnes, Prisoners May Be Used to Fill Clinical Trial Patient Shortage,
OUTSOURCING-PHARMA.COM, Aug. 17, 2006, http://www.outsourcing-pharma.com/ClinicalDevelopment/Prisoners-may-be-used-to-fill-clinical-trial-patient-shortage.
144. 2006 IOM REPORT, supra note 3, at 121.
145. Id.
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Review boards can have blatant conflicts of interest. The one policing the
Fabre clinic was founded by Louis Fabre, the same doctor who ran the clinic.
Miami-based Southern IRB has overseen testing at SFBC and is owned by
Alison Shamblen, 48, wife of E. Cooper Shamblen, 67, SFBC’s vice president
of clinical operations.146

When such conditions and conflicts intersect with human subjects from
vulnerable communities, there can be harmful effects for both the participants
and research integrity. The Bloomberg Markets report details how
undocumented persons evade basic research protocols and simultaneously
participate in multiple clinical trials to get much needed cash.147 This puts their
lives at risk in that unknown drug interactions can be deadly. Moreover, taking
multiple drugs at once muddies the data the researchers analyze in order to
determine safety and efficacy.148
These are far from the only examples of questionable practices in the
modern research industry. Pfizer has partially settled a lawsuit stemming from
clinical trials of Trovan in Nigeria,149 where they allegedly tested a drug on sick
children without written consent or legitimate ethics approval, leading to eleven
deaths.150 A recent Congressional sting operation highlighted deficiencies in
146. Evans et al., supra note 135, at 2.
147. For example,
Roberto Alvarez, 36, an Argentine in the U.S. on a visa; Efrain Sosa, 35, a Cuban native; and
Marlon Matos, a 27 year old immigrant from Venezuela, say they’ve participated in more
than one clinical trial in Miami at the same time or gone from one test to another, ignoring
required waiting periods. They say they do it for the money, without telling the test centers,
and that no one has ever caught them violating the rule.
“We maintain many safeguards to help ensure that the participants of our clinical trials
are not participating simultaneously in multiple clinical trials,” SFBC’s Hantman says. SFBC
fingerprints participants to keep track of their tests at the company, he says. “Unfortunately,
there is no clearing house that we’re aware of that would allow us to find if they were
participating in another trial at the same time.”
In April, Alvarez signed up for a 36-day clinical trial at Miami testing company Elite
Research Institute for a new sustained-release form of donepezil, an Alzheimer’s drug that
Tokyo-based Eisai Co. sells in the U.S. with New York-based Pfizer. At the time, Alvarez
was in the middle of a 212-day test sponsored by Madison, New Jersey-based Wyeth at
SFBC for an experimental muscular dystrophy drug, according to consent forms he signed. “I
hop around to get around that,” says Alvarez, a part time construction worker. . . . “They ask,
but I just don’t tell them. Everybody does that.”

Id. at 3.
148. “Steve Simon, a research biostatistician at Children’s Mercy Hospital in Kansas City,
Missouri, says that when people participate in more than one clinical trial at a time, it can be
harmful to people and research. ‘When neither researcher knows about potential interactions
with the other trial, that raises concerns about scientific validity. . . . You don’t know how
these things might interact. It’s asking for trouble.’”

Id.
149. “Pfizer signed a $75 million agreement Thursday with Nigerian authorities to settle
criminal and civil charges that the pharmaceutical company illegally tested an experimental
drug on children during a 1996 meningitis epidemic. . . . Charges filed against Pfizer by
Nigeria’s federal government, which is seeking about $6 billion in damages, are unaffected
by the settlement.”

Joe Stephens, Pfizer to Pay $75 Million to Settle Trovan-Testing Suit, WASH. POST, July 31,
2009, at A15.
150. Joe Stephens, Pfizer Reaches Settlement in Nigerian Drug-Trial Case, WASH.
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both IRB oversight of proposed clinical trials and government oversight of
private IRBs. Based on a previously rejected (and dangerous151) application, the
Government Accountability Office proposed a fake clinical trial and submitted
it to three private IRBs, in which one (Coast IRB152) approved the study. The
GAO also created a transparently fictitious IRB153 to see if the Department of
Health and Human Services would register it. It did. Large surveys also
continue to show that there are pervasive conflicts of interest between IRBs and
industry.154 This all suggests that the very system deferred to by the IOM as
being presumptively virtuous enough to soften the current “strong
protectionist” stance on prison research is questionable at best. Moreover, it
highlights the extent to which the conditions that shape human subjects abuse
are not simply those that come from the living conditions of participants, but
also those that shape the financial interests of the industries conducting the
research. While there has been conversation about the changes needed in prison
environments before such research can be truly ethical, there needs to be more
thought about the changes that need to occur within the research industry
before they are once again given greater access to prison populations.
3. Substantive Critique
This leads to the third critique: isolating the ethical questions surrounding
the use of prisoners as human subjects from broader normative paradigms
directly relevant to prisoners’ daily lives–most importantly, human rights–may
obscure the full impact of the IOM recommendations. The methodological
critique concerned itself with how the IOM Committee came to its

POST, Apr. 4, 2009, at A3.
151. A reviewer from one of the IRBs that rejected the fake GAO clinical trial proposal
said, “We realized it was a terrible risk for the patient . . It is the worst thing I have ever
seen.” Alicia Mundy, Sting Operation Exposes Gaps in Oversight of Human Experiments,
WALL ST. J., Mar. 26, 2009, available at http://online.wsj.com/article/SB12381117957235
3181.html.
152. Jesse Reynolds notes,
Coast seems to epitomize the shortcomings of private companies which approve research on
humans. It advertises its fast 48 hour turnaround time on submissions, and even publishes a
coupon for a free review, offering prospective customers to “take us for a free test drive” and
to “coast through your next study.” In the last five years, Coast approved all 356 submitted
protocols. And in the case of the GAO’s faked application, Coast didn’t even examine the
submitted data.

Jesse Reynolds, Human Research Subjects Protection: Under Fire From Congress,
BIOPOLITICAL TIMES, Mar. 31, 2009, http://www.biopoliticaltimes.org/article.php?id=4614.
153. “The committee, working with the Government Accountability Office, Congress’s
investigatory arm, named the CEO of the fake IRB Truper Dawg, after a staffer’s threelegged dog, now deceased. Other fake names included ‘April Phuls’ and “Timothy Wittless,”
which lawmakers said should have signaled irregularities to HHS. The department registered
the IRB.” Mundy, supra note 151.
154. See, e.g., Eric G. Campbell et al., Financial Relationships Between Institutional
Review Board Members and Industry, 355 NEW ENG. J. MED. 2321 (2006).
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recommendations and the contextual critique examined which set of conditions
the Committee acknowledged as relevant to its deliberations. This substantive
critique deals with how the Committee engages the substance of its ethical
deliberations with other normative paradigms relevant to the treatment of
human subjects. Notably, the IOM’s failure to meaningfully engage with
established human rights norms and standards—such as those laid out in the
Universal Declaration of Human Rights—is troubling. To be sure, the IOM
discusses the ways in which prison settings complicate traditional notions of
informed consent and non-coercion. But it is one thing to discuss these
complications as merely a matter of research ethics. It is quite another to
engage them as a matter of human rights.
Although the Institute of Medicine might resist this type of dual
engagement with both ethics and human rights as being too far afield from its
mandate and area of expertise, such responses to this critique fail to
acknowledge the interconnected nature of biomedical ethics and human
rights.155 University of Pennsylvania bioethicist Arthur Caplan has noted,
“bioethics was born from the ashes of the Holocaust.”156 Similarly, human
rights took on a new importance during this period. George Annas notes in his
timely book American Bioethics: Crossing Human Rights and Health Law
Boundaries that ethics and human rights “have a natural symbiosis . . . [that]
can be most closely discerned in crimes against humanity that have historically
involved physicians, such as torture, imprisonment, execution, and lethal
human experimentation.”157 This passage draws attention to the unique role
prisoners have played in the development of ethics and international human
rights. While they are often considered to be two distinct fields, a growing
number of scholars are realizing that “[h]uman rights and medical ethics are
complementary, and the use of the two together maximizes the protection
available to the vulnerable patient.”158
Michael Peel identifies at least two differences between human rights and
ethics. First, human rights “focus[es] on state-level action rather than a personto-person relationship.”159 Second, the notion of benevolence—at the heart of
any ethical discussion—is absent from human rights in that “rights do not
depend on the empathy of other actors.”160 Despite these distinctions, bringing
155. An example of the increasing awareness of the relationship between bioethics and
human rights can be seen in UNESCO’s UNIVERSAL DECLARATION OF BIOETHICS AND
HUMAN RIGHTS (2005). See generally Roberto Andorno, Global Bioethics at UNESCO: In
Defence of the Universal Declaration on Bioethics and Human Rights, 33 J. MED. ETHICS
150 (2007).
156. GEORGE J. ANNAS, AMERICAN BIOETHICS: CROSSING HUMAN RIGHTS AND HEALTH
LAW BOUNDARIES 161 (2005).
157. Id. at xiv.
158. Michael Peel, Human Rights and Medical Ethics 98 J. ROYAL SOC’Y. MED. 171,
173 (2005).
159. Id. at 172.
160. Id.
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a human rights framework into conversations on the research ethics pertaining
to prisoners’ participation as human subjects has at least three major benefits.
First, human rights “give fundamental protections that allow equal participation
in a democracy….[that] prevent the worst excesses of democracy because no
society can vote to take those rights away.”161 For prisoners who have most of
their freedoms restricted, a human rights framing draws attention to core rights
that may not receive the same sensitivity under a unilateral focus on research
ethics. Second, “conventional bioethics has difficulty addressing broad issues
of inequity,”162 an issue that is at the center of any human rights analysis.
Lastly, bioethics’ emphasis on individual autonomy163 can mask how group
dynamics can lead individuals to choose to partake in research that may
ultimately lead to unethical if not harmful outcomes. Human rights frameworks
offer a safety net to ensure that bioethics’ privileging of individual autonomy
over other principles does not trump core rights that vest in every human.
The connections between bioethics and human rights is far from
coincidental; vesting internationally agreed upon rights in every person and
creating ethical standards for research involving human subjects were and
continue to be seen as two sides of the same coin shielding humanity from
reliving its darkest moments. As Annas points out in American Bioethics, this is
evident in the documents discussing these normative commitments:
The voluntary consent of the human subject is absolutely essential. This
means that the person involved should have legal capacity to give consent;
should be so situated as to be able to exercise free power of choice, without
the intervention of any element of force, fraud, deceit, duress, over-reaching,
or other ulterior form of constraint or coercion . . . .164
Everyone has the right to a standard of living adequate for the heath and wellbeing of himself and of his family, including food, clothing, housing and
medical care and necessary social services . . . .165

As a whole and in their cited portions, these documents take on two separate
issues—one placing informed consent and non-coercion at the cornerstone of
all ethical human subject research, the other addressing the human right to
medical care. Together, however, they make a more perfect union: that
biomedical ethics—and in particular, research ethics—are most legitimate
when subjects’ human rights are secure. It makes little sense for ethical
161. Id. at 171.
162. Paul Farmer and Nicole Gastuneau Campos, New Malaise: Bioethics and Human

Rights in the Global Era, 32 J.L. MED. & ETHICS 243, 245 (2004).
163. See generally Paul Root Wolpe, The Triumph of Autonomy in American Bioethics:
A Sociological View, in Bioethics and Society: Constructing the Ethical Landscape
(Raymond DeVries & Janardan Subedi, eds., 1998).
164. The Nuremberg Code (1947), available at http://www.hhs.gov/ohrp/references/
nurcode.htm.
165. Universal Declaration of Human Rights, G.A. Res. 217 (III) A, U.N. Doc.
A/RES/217(III) (Dec. 10, 1948).
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inquiries to isolate themselves from human rights. Continuing to do so can lead
to situations where ethics can be misused to exacerbate human rights
violations; subjects living in conditions where basic human rights are not
upheld might agree to participate in studies that they otherwise might not—a
subtle but important form of coercion.
The wide-ranging human rights violations documented in prisons by
organizations such as the ACLU and Human Rights Watch suggest that
conditions are often deplorable: inadequate medical care, unprovoked physical
assaults, and sexual coercion are but a few of these concerns.166 And the
relations between guards and prison populations raise even brighter human
rights red flags. As an example, an October 2006 Human Rights Watch report
documents how many prisons routinely use terror tactics such as subjecting
prisoners to snarling guard dogs as population control measures.167
Biomedical and research ethics are not the only source of normative
commitments by which physicians and researchers should abide. As such, the
ethical challenges raised by proposals to loosen current restrictions on using
prisoners as human subjects may very well be a tremendous opportunity to
fully integrate ethical deliberations with human rights sensibilities. What makes
their integration so urgent is that without it, one set of norms developed to
protect vulnerable subjects can be used unwittingly to destabilize the other. To
prevent this, ethical and human rights frameworks must be seen as
interconnected rather than disjoined. Otherwise, one ethic for treating people
with dignity can be paradoxically used to exploit holes in the other—a
strikingly unfortunate ethical outcome for subjects caught in the crosshairs.
Is it possible to conduct ethical research with prisoners in a way that is
consistent with various human rights norms? This is an important empirical and
legal question that is beyond this Part’s narrow focus on a substantive deficit
within the IOM’s chosen ethical framework.168 But without this deeper analysis
and integrated framework that substantively brings both ethical and human
rights considerations directly into its policy deliberations, the IOM’s
166. For example, California’s prison health care system was deemed to be so
substandard and harmful to prisoners, a federal district court judge placed it under
receivership. The court noted, “By all accounts, the California prison medical care system is
broken beyond repair. The harm already done in this case to California’s prison inmate
population could not be more grave, and the threat of future injury and death is virtually
guaranteed in the absence of drastic action.” Findings of Fact and Conclusions of Law Re
Appointment of Receiver at 1, Plata v. Schwarzenegger, No. C01-1351 TEH (N.D. Cal. Oct.
3, 2005), available at http://www.cprinc.org/docs/court/PlataFindingsFactConclusionsLaw
1005.pdf. See generally HUMAN RIGHTS WATCH, NO ESCAPE: MALE RAPE IN PRISON (2001),
available at http://www.hrw.org/reports/2001/prison/index.htm; HUMAN RIGHTS WATCH,
ALL TOO FAMILIAR: SEXUAL ABUSE OF WOMEN IN U.S. STATE PRISONS (1996), available at
http://www.hrw.org/reports/1996/Us1.htm.
167. See generally HUMAN RIGHTS WATCH, CRUEL AND DEGRADING: THE USE OF DOGS
FOR CELL EXTRACTIONS IN U.S. PRISONS (2006).
168. For an interesting discussion on the problems associated with research in today’s
prisons, see Reiter, supra note 1, at 520-34.
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recommendation to loosen current restrictions might have the unintended
effects of exposing prisoners to additional health risks and exacerbating
ongoing human rights violations.
CONCLUSION
To date, the recommendations put forth by the 2006 IOM report have not
led to any changes in the regulations governing human subjects research with
prisoners, although changes to Subpart C are still under consideration. This
Article argued that the recommendations put forth by the IOM should not be
adopted due to (1) its methodological shortcomings that forgo an empirical
understanding of how research ethics interact with prison conditions in favor of
a literature review, (2) its contextual limitations that situate prisoners’
vulnerability to abuse as only a product of prison conditions rather than also
looking at how market conditions might exacerbate such concerns, and (3) its
substantive limitations whereby the proposed ethical framework fails to engage
other normative commitments relevant to human subject protection such as
human rights. Before the Department of Health and Human Services moves
forward with any further consideration of the IOM report, these issues should
be taken seriously.
It is likely that state and federal governments will continue to face
numerous ethical dilemmas involving prisoners. As an example, lawmakers in
South Carolina have considered legislation that attempts to relieve the state’s
kidney shortage by shaving 180 days off inmates’ sentences if they agree to
become organ donors.169 Further developments in human biotechnology may
also come into play. A tremendous amount of excitement has centered around
the therapeutic potential of human embryonic stem cell research. And, given
the shortage of eggs available to pursue certain types of stem cell research with
human embryos,170 it is not difficult to imagine a state providing similar
incentives to incarcerated women who might agree to become egg donors.
Outside of the prison environment, ethics are also likely to impact regulatory
policy and administrative agencies over the next several years, whether it is the
appropriate regulation of reproductive and genetic technologies by the Food
and Drug Administration or other regulatory bodies, increased oversight of
direct-to-consumer genetic tests by the Federal Trade Commission, or increased
oversight of the use of genetic technologies by the Justice Department.
These are complicated issues, pitting what some might call the ability to
save and improve human life against maintaining all people’s human dignity.
What is important is that as biomedical and research ethics are sought to inform
169. See generally Associated Press, Wanna Cut Your Jail Time? Donate A Kidney!,
CBSNEWS.COM, Mar. 8, 2007, http://www.cbsnews.com/stories/2007/03/08/national/main
2548860.shtml.
170. See generally Geoff Brumfiel, Egg Shortage Hits Race to Clone Human Stem
Cells, 453 NATURE 828 (June 11, 2008).

41_82_OBASOGIE-PRINTER PROOF.DOC

82

11/9/10 4:30 PM

STANFORD JOURNAL OF CIVIL RIGHTS & CIVIL LIBERTIES

[VI:1

increasing areas of regulatory policy that there is a broad recognition that
ethics are not, in and of themselves, a source of public policy. While the
contribution of ethical inquiries are invaluable, this Article has argued that too
much is at stake when such policy recommendations are not methodologically
robust, do not acknowledge the rich and overlapping contexts that inform the
issue, and isolate one set of moral principles without a substantive engagement
with other relevant norms. Regrettably, in these and other failures, the IOM’s
report may very well come to stand for the proposition of how not to infuse
ethics into regulatory policy.

